


THE ROLE OF NITRIC OXIDE IN TYPE 2 DIABETES



Editors:

Asghar Ghasemi
Khosrow Kashfi
Zahra Bahadoran

Bentham Books

The Role of Nitric Oxide in Type 2 Diabetes

Edited by

Asghar Ghasemi

*Endocrine Physiology Research Center,
Research Institute for Endocrine Sciences,
Shahid Beheshti University of Medical Sciences,
Tehran, Iran*

Khosrow Kashfi

*Department of Molecular, Cellular,
and Biomedical Sciences,
Sophie Davis School of Biomedical Education,
City University of New York
School of Medicine,
New York, USA
Graduate Program in Biology,
City University of New York Graduate Center,
New York, USA*

Zahra Bahadoran

*Nutrition and Endocrine Research Center,
Research Institute for Endocrine Sciences,
Shahid Beheshti University of Medical Sciences,
Tehran, Iran*

The Role of Nitric Oxide in Type 2 Diabetes

Editors: Asghar Ghasemi, Khosrow Kashfi, Zahra Bahadoran

ISBN (Online): 978-981-5079-81-4

ISBN (Print): 978-981-5079-82-1

ISBN (Paperback): 978-981-5079-83-8

© 2022, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: subscriptions@benthamscience.net



CONTENTS

FOREWORD	i
PREFACE	iii
REFERENCES	v
LIST OF CONTRIBUTORS	vii
CHAPTER 1 PATHOPHYSIOLOGY OF TYPE 2 DIABETES: A GENERAL OVERVIEW OF GLUCOSE AND INSULIN HOMEOSTASIS	1
<i>Asghar Ghasemi and Khosrow Kashfi</i>	
INTRODUCTION	1
EPIDEMIOLOGY OF DIABETES	2
DIAGNOSIS OF DIABETES	3
GLUCOSE HOMEOSTASIS	3
POST-ABSORPTIVE STATE: THE FASTING STATE	4
Glucose Production	5
Glucose Utilization	6
POST-PRANDIAL STATE	6
MECHANISMS UNDERLYING GLUCOSE HOMEOSTASIS	7
Central Mechanisms of Glucose Homeostasis	7
Glucose Sensing by Neurons	9
Peripheral Mechanisms of Glucose Homeostasis	9
INSULIN	10
Insulin Secretion	10
Mechanism of Insulin Secretion	10
Box 1 Circulating Insulin Concentrations	12
Box 2 Technical Considerations on Circulating Insulin Measurement	13
Insulin Signaling Pathways	14
Pathophysiology of Type 2 Diabetes	15
Insulin Resistance	16
β -cell Dysfunction	18
CONCLUDING REMARKS	19
CONSENT FOR PUBLICATION	20
CONFLICT OF INTEREST	20
ACKNOWLEDGEMENT	20
REFERENCES	20
CHAPTER 2 NITRIC OXIDE: A BRIEF HISTORY OF DISCOVERY AND TIMELINE OF ITS RESEARCH	27
<i>Asghar Ghasemi and Khosrow Kashfi</i>	
INTRODUCTION	27
HISTORY OF NO FIELD	28
Diabetes-Related NO Research	32
CONCLUDING REMARKS	32
CONSENT FOR PUBLICATION	33
CONFLICT OF INTEREST	33
ACKNOWLEDGEMENT	33
REFERENCES	33
CHAPTER 3 IMPAIRED NITRIC OXIDE METABOLISM IN TYPE 2 DIABETES: AT A GLANCE	39
<i>Zahra Bahadoran, Mattias Carlström, Parvin Mirmiran and Asghar Ghasemi</i>	

INTRODUCTION	40
ROLE OF NO IN GLUCOSE AND INSULIN HOMEOSTASIS	42
T2D AND WHOLE-BODY NO METABOLISM	44
NO DEFICIENCY IN T2D	44
T2D and Circulating NO: an Epidemiologic Point of View	47
Underlying Mechanisms of Impaired NO Metabolism/Action in T2D	48
Impaired L-Arginine NOS-NO Pathway	49
Impaired NO ₃ -NO ₂ -NO Pathway	52
Impaired NO Transport	53
Impaired NO Signaling	54
CONCLUDING REMARKS	54
CONFLICT OF INTEREST	55
ACKNOWLEDGEMENT	55
CONSENT OF PUBLICATION	55
REFERENCES	55
CHAPTER 4 ASYMMETRICAL DIMETHYL ARGININE, NITRIC OXIDE, AND TYPE 2	
DIABETES	67
<i>Zahra Bahadoran, Mattias Carlström, Parvin Mirmiran and Asghar Ghasemi</i>	
INTRODUCTION	68
ADMA BIOSYNTHESIS AND METABOLISM	68
Adma and Regulation of No Synthesis	71
Cellular Uptake of ADMA	71
Inhibitory Effects of ADMA on NOS Expression and Activity	72
ADMA and T2D	73
DDAH and T2D: Lessons from Genetic Studies	73
Plasma and Tissue Concentrations of ADMA in T2D	74
Plasma ADMA Levels and Risk of Diabetic Complications	75
Other Methylarginines and T2D	77
Pharmaceutical Interventions for Elevated Adma	78
CONCLUDING REMARKS	79
CONFLICT OF INTEREST	80
ACKNOWLEDGEMENT	80
CONSENT OF PUBLICATION	80
REFERENCES	80
CHAPTER 5 NITRIC OXIDE-RELATED ORAL MICROBIOTA DYSBIOSIS IN TYPE 2	
DIABETES	87
<i>Zahra Bahadoran, Pedro González-Muniesa, Parvin Mirmiran and Asghar Ghasemi</i>	
INTRODUCTION	88
AN OVERVIEW OF ORAL MICROBIOTA	88
Oral Nitrate-Reducing Bacteria	90
Oral Nitrate Reduction and Nitric Oxide Homeostasis	93
Changes in Oral Microbiota in T2D	95
Mechanisms Linking Oral Dysbiosis with Impaired Glucose and Insulin Homeostasis	97
Oral Nitrate-Reducing Bacteria and Nitric Oxide Metabolism in T2D	99
CONCLUDING REMARKS	99
CONSENT FOR PUBLICATION	100
CONFLICT OF INTEREST	100
ACKNOWLEDGEMENTS	100
REFERENCES	100

CHAPTER 6 NITRIC OXIDE AND TYPE 2 DIABETES: LESSONS FROM GENETIC STUDIES	107
<i>Zahra Bahadoran, Parvin Mirmiran, Mattias Carlström and Asghar Ghasemi</i>	
INTRODUCTION	107
A BRIEF OVERVIEW OF NOS ENZYMES: GENE STRUCTURE AND CHROMOSOMAL LOCALIZATION	108
Genetically-Modified Nos Enzymes and Impaired Glucose and Insulin Homeostasis	111
Common Polymorphisms of NOS Enzymes	113
Common Polymorphisms of nNOS and iNOS	113
Common Polymorphisms of eNOS	114
The eNOS Polymorphisms and Serum NO Metabolites	116
The eNOS Polymorphisms and Development of Insulin Resistance	116
The eNOS Polymorphisms and Development of T2D	117
The eNOS Polymorphisms and T2D Complications	118
CONCLUDING REMARKS	119
CONSENT FOR PUBLICATION	119
CONFLICT OF INTEREST	119
ACKNOWLEDGEMENT	119
REFERENCES	120
CHAPTER 7 ROLE OF NITRIC OXIDE IN DIABETIC WOUND HEALING	128
<i>Hamideh Afzali, Tara Ranjbar, Khosrow Kashfi and Asghar Ghasemi</i>	
INTRODUCTION	128
Types of Wound	129
Pathophysiology of Diabetic Foot Ulcer	130
Peripheral Neuropathy	130
Peripheral Arterial Disease (PAD)	130
PHASES OF WOUND HEALING	131
Hemostasis (Coagulation)	131
Inflammation	132
Proliferation	133
Tissue Remodeling	134
CHANGES IN HEALING PHASES IN DIABETIC WOUNDS	134
Nitric Oxide Synthesis in the Skin	135
Expression of NOS Isoforms in the Skin	136
NOS-Independent NO Synthesis in the Skin	136
The Role of Surface Bacteria in Skin Production of NO	136
UVA Radiation and NO Production	137
NO AND WOUND HEALING	138
NO Metabolites as an Index of Wound NO	138
Role of NO different Phases of Wound Healing	139
Inflammation	139
Vasculogenesis and Angiogenesis	140
Re-epithelialization	141
NO AND DIABETIC WOUND HEALING	141
Role of NO Different Phases of Diabetic Wound Healing	143
NO AND THERAPEUTIC STRATEGIES FOR DIABETIC WOUND	143
L-arginine	147
Regulation of NOS Expression	147
Acidified Nitrite	148
NO Donor Systems	148

CONCLUDING REMARKS	150
CONSENT FOR PUBLICATION	150
CONFLICT OF INTEREST	150
ACKNOWLEDGEMENT	150
REFERENCES	150
CHAPTER 8 ROLE OF NITRIC OXIDE IN TYPE 2 DIABETES-INDUCED OSTEOPOROSIS	161
<i>Nasibeh Yousefzadeh, Sajad Jeddi, Khosrow Kashfi and Asghar Ghasemi</i>	
INTRODUCTION	161
NITRIC OXIDE AND BONE: A BRIEF OVERVIEW	163
NOS Expression in the Bone Cells	163
TYPE 2 DIABETES AND BONE INDICES	164
Type 2 Diabetes and BMD	164
Type 2 Diabetes and Trabecular and Cortical Bone Microarchitectures	164
Type 2 Diabetes and Bone Cells	165
Bone NO Bioavailability in Type 2 Diabetes	167
BONE REMODELING	167
Bone Remodeling in Type 2 Diabetes: Role of NO	168
NITRIC OXIDE-BASED TREATMENT OF DIABETOPOROSIS	170
Possible Strategies for Nitric Oxide-based Treatment of Diabetoporosis	171
CONCLUDING REMARKS	173
CONSENT OF PUBLICATION	173
CONFLICT OF INTEREST	174
ACKNOWLEDGEMENT	174
REFERENCES	174
CHAPTER 9 HYPERURICEMIA, TYPE 2 DIABETES AND INSULIN RESISTANCE: ROLE OF NITRIC OXIDE	190
<i>Zahra Bahadoran, Parvin Mirmiran, Khosrow Kashfi and Asghar Ghasemi</i>	
INTRODUCTION	191
A BRIEF OVERVIEW OF URIC ACID METABOLISM AND FUNCTION	192
Uric Acid Synthesis In Human: Role of XOR	192
Regulation of Circulating Uric Acid Levels	192
Physiologic Roles of Normal Uric Acid Levels	194
Pathological Effects of Hyperuricemia	194
HYPERURICEMIA, T2D AND INSULIN RESISTANCE	195
Epidemiological Evidence	195
Experimental and Clinical Evidence	196
Underlying Mechanisms Connecting UA to Insulin Resistance and T2D	197
Role of No in Hyperuricemia-Induced Dysglycemia and Insulin Resistance	198
CONCLUDING REMARKS	201
CONSENT OF PUBLICATION	202
CONFLICT OF INTEREST	202
ACKNOWLEDGEMENT	202
REFERENCES	203
CHAPTER 10 THERAPEUTIC MANAGEMENT OF TYPE 2 DIABETES: THE NITRIC OXIDE AXIS	210
<i>Tara Ranjbar, Jennifer L. O'Connor and Khosrow Kashfi</i>	
INTRODUCTION	211
BIGUANIDES	212
General Mechanism of Action	212

Metformin and Its Nitric Oxide Connection	213
THIAZOLIDINEDIONES	214
General Mechanism of Action	214
Thiazolidinediones and Their Nitric Oxide Connection	215
SULFONYLUREAS	215
General Mechanism of Action	215
Sulfonylurea and Their Nitric Oxide Connection	216
MEGLITINIDES	217
General Mechanism of Action	217
Meglitinides and Their Nitric Oxide Connection	217
DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS	218
General Mechanism of Action	218
DPP-4 Inhibitors and Their Nitric Oxide Connection	219
GLUCAGON-LIKE PEPTIDE 1 RECEPTOR (GLP-1) AGONISTS	219
General Mechanism of Action	219
GLP-1 Receptor Agonists and Their Nitric Oxide Connection	220
ALPHA-GLUCOSIDASE INHIBITORS	221
General Mechanism of Action	221
Alpha-Glucosidase Inhibitors and Their Nitric Oxide Connection	221
SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS (SGLT2) INHIBITORS	221
General Mechanism of Action	221
SGLT2 Inhibitors and Their Nitric Oxide Connection	222
NITRATE-NITRITE-NO PATHWAY: A POTENTIAL THERAPEUTIC TARGET FOR T2D?	223
CONCLUDING REMARKS	224
CONSENT FOR PUBLICATION	224
CONFLICT OF INTEREST	225
ACKNOWLEDGMENTS	225
REFERENCES	225
CHAPTER 11 BRAIN INSULIN RESISTANCE, NITRIC OXIDE AND ALZHEIMER'S DISEASE PATHOLOGY	238
<i>Zhe Pei, Kuo-Chieh Lee, Amber Khan and Hoau-Yan Wang</i>	
INTRODUCTION	239
INSULIN RECEPTOR SIGNALING AND ITS INTERACTION WITH NO SYSTEM	239
The Inter-Relationship between Brain Insulin Signaling and Memory/Cognitive Performance	241
The Role of No in Brain Insulin Resistance and Cognitive Performance	244
CONCLUDING REMARKS	249
CONSENT FOR PUBLICATION	249
CONFLICT OF INTEREST	249
ACKNOWLEDGEMENT	250
REFERENCES	250
CHAPTER 12 ARGININE, NITRIC OXIDE, AND TYPE 2 DIABETES	260
<i>Parvin Mirmiran, Zahra Bahadoran, Khosrow Kashfi and Asghar Ghasemi</i>	
INTRODUCTION	260
PLASMA ARG FLUX	261
Arginine Biosynthesis Pathways	262
Arginine Catabolic Pathways	263
Arginase and Urea Production	264
Arg and NO Production	265

Intracellular Arg Pools and NO Production	266
Pharmacokinetics of Arg	267
ARG, INSULIN RESISTANCE, AND T2D	269
Changes in Arg Metabolism and Pathophysiology of T2D	269
Arg Supplementation in T2D	271
Arg Supplementation in Metabolic Syndrome and its Components	273
Doses of Arg Supplementation	274
CONCLUDING REMARKS	275
CONSENT OF PUBLICATION	275
CONFLICT OF INTEREST	275
ACKNOWLEDGEMENT	275
REFERENCES	275
CHAPTER 13 CITRULLINE, NITRIC OXIDE, AND TYPE 2 DIABETES	284
<i>Parvin Mirmiran, Zahra Bahadoran, Khosrow Kashfi and Asghar Ghasemi</i>	
INTRODUCTION	285
CIT BIOSYNTHESIS PATHWAYS	286
Intestinal Biosynthesis of Cit	286
Extra-Intestinal Biosynthesis of Cit	289
Gut-Liver Metabolism of Cit	289
INTERORGAN EXCHANGE OF CIT AND ARG PRODUCTION	290
Cit and No Production	291
Pharmacokinetics of Cit	292
CIT AND T2D	293
Change of Cit Metabolism in T2D	293
Cit Supplementation, T2D, and its Complications	294
CONCLUDING REMARKS	296
CONSENT FOR PUBLICATION	296
CONFLICT OF INTEREST	296
ACKNOWLEDGEMENT	296
REFERENCES	296
CHAPTER 14 NITRATE, NITRITE AND TYPE 2 DIABETES	303
<i>Zahra Bahadoran, Parvin Mirmiran, Khosrow Kashfi and Asghar Ghasemi</i>	
INTRODUCTION	304
INORGANIC NITRATE AND NITRITE: A NUTRITIONAL PERSPECTIVE	305
Food and Dietary Sources of Inorganic NO ₃ and NO ₂	305
Dietary Intake of NO ₃ and NO ₂ and Risk of Diseases	306
EFFECTS OF INORGANIC NO₃ AND NO₂ ON TYPE 2 DIABETES AND INSULIN	
RESISTANCE	308
Animal Studies	308
Human Clinical Trials	312
WHY BENEFICIAL EFFECTS OF INORGANIC NO₃-NO₂ IN ANIMALS DO NOT	
TRANSLATE INTO HUMAN CLINICAL TRIALS?	316
CONCLUDING REMARKS	317
CONFLICT OF INTEREST	318
ACKNOWLEDGEMENT	318
CONSENT OF PUBLICATION	318
REFERENCES	318

CHAPTER 15 POTENTIAL APPLICATIONS OF NITRIC OXIDE DONORS IN TYPE 2	
DIABETES	324
<i>Zahra Bahadoran, Parvin Mirmiran, Mehrnoosh Bahmani and Asghar Ghasemi</i>	
INTRODUCTION	325
A BRIEF OVERVIEW OF NITRIC OXIDE DONORS	326
Box. 1 Angeli's Salt	331
NO DONORS AND INSULIN-GLUCOSE HOMEOSTASIS	331
Sodium Nitroprusside	331
S-nitrosothiols	336
NONOates	339
CONCLUDING REMARKS	339
CONSENT FOR PUBLICATION	340
CONFLICT OF INTEREST	340
ACKNOWLEDGEMENT	341
REFERENCES	341
SUBJECT INDEX	572

FOREWORD

The global obesity and overweight pandemic that causes the increasing number of patients with type 2 diabetes (T2D) is a major challenge for healthcare systems worldwide. With its cardiovascular complications, this metabolic disorder is one of the major causes of morbidity and mortality worldwide. On top of lifestyle and dietary recommendations to prevent or control T2D, a tremendous amount of research has been invested in understanding disease mechanisms better and developing novel drugs. Even if new pharmaceuticals have entered the clinical arena in recent years, metformin is still the first-line option, even after more than 60 years. This points to the necessity to develop therapeutic strategies based on biological pathways that have not previously been the center focus of diabetes research. Such an area is nitric oxide research.

Nitric oxide (NO) is one of the universal signaling molecules in mammalian species. When discovered in the 1980s, it portrayed a completely novel principle, where a small, unstable, and reactive free radical gas was involved in cell signaling. Its chemical nature makes it react with other radicals and transition metals; one example of the latter is how NO activates soluble guanylyl cyclase to generate cGMP, a classical form of NO signaling that, e.g., induces vasodilation. Binding to heme in cytochrome c oxidase, leading to inhibition of mitochondrial respiration, is another example. In addition, post-translational nitrosation of many proteins, which regulates their function, is another signaling modality of NO. This pluripotency of NO explains why it is involved in regulating such diverse processes as cardiovascular function, metabolism, inflammation, and nerve signaling. The canonical pathway for NO generation involves the substrates L-arginine and molecular oxygen and specific NO synthases (N.O.S.s), of which there are three isoforms. Two of them are more constitutively expressed (endothelial N.O.S. and neuronal N.O.S.), while an inducible isoform (inducible N.O.S.) is involved during inflammatory conditions. The half-life of NO is within seconds due to binding to heme or to rapid oxidation, which forms the inorganic anions nitrite and nitrate that are widely used both *in vitro* and *in vivo* as more stable surrogate measures of NO.

Interestingly, discoveries in the mid-1990s revealed that these supposedly inert anions could be recycled back to bioactive NO and other reactive nitrogen species. The first step in this nitrate-nitrite-NO pathway involves active uptake of circulating nitrate in the salivary glands, after which nitrate in the saliva is reduced to nitrite by oral commensal bacteria, a function that mammalian cells are poor in performing. Swallowed salivary nitrite is rapidly absorbed in the gut, and then there are several pathways for further reduction to NO. Of interest is that the nitrate-nitrite-NO pathway can be fueled by a diet where certain vegetables contain high levels of nitrate. This pathway can be viewed as a parallel backup system to the L-arginine-NOS-NO pathway, perhaps with more importance during hypoxic and ischemic conditions.

This book, to my knowledge, is the first of its kind, Asghar Ghasemi and collaborators present a comprehensive and detailed overview of our current knowledge on the role of NO in T2D. The rationale for this book is the growing evidence of the involvement of the NO system in diabetes. An impressive amount of research has clarified that NO is deeply involved on many levels to uphold metabolic homeostasis and that NO signaling is negatively affected in T2D. Of interest is that several of the pharmaceuticals used in T2D affect the NO system and perhaps even more so by the drugs we use to treat diabetic cardiovascular complications. Experimental works in animal models of obesity or T2D show promising results with interventions aimed to increase NO signaling. However, translation into human studies has so far been less successful, but larger and more prolonged studies are clearly needed. There is an

ii

intriguing dietary aspect here since NO bioavailability can be boosted by nitrate in our diet, which is supported by epidemiological studies showing that green leafy vegetables, which are high in nitrate, stand out as particularly protective against the development of T2D and cardiovascular disease. Clearly, more research on the role of NO in metabolic regulation and T2D is needed, and in this context, the present book is of great value to anyone interested in this field of research.

Eddie Weitzberg, M.D., Ph.D.

Professor, Senior Consultant

Department of Physiology and Pharmacology, Karolinska Institutet
Department of Perioperative Medicine and Intensive Care, Karolinska University
Hospital Stockholm
Sweden

PREFACE

Nitric oxide (NO) is a colorless, odorless, primordial flammable gas that has been present in the earth's atmosphere from the beginning of time. Historically, NO was regarded as an industrial toxin or pollutant generated in many industries; however, it is now well recognized that NO is endogenously produced and has an important biological role in most mammalian tissues. The vital role of NO in human biology was recognized in 1992 when the journal *Science* introduced NO as the “Molecule of the Year” [1] and in 1998 when the Nobel Prize in Physiology and Medicine was awarded to Robert F. Furchgott, Louis J. Ignarro, and Ferid Murad for the major discoveries surrounding it and establishing its role as a messenger molecule.

According to the World Health Organization (WHO), the prevalence of obesity across the globe has approximately doubled since 1980. In the U.S., about one-third of the adult population is obese, and an additional one-third is overweight [2]. Obesity is the fastest-growing lethal *disease* in Western and developing countries. People do not die due to obesity itself but from its complications, which shorten the life span [3, 4]. In addition, obesity leads to many other diseases, including type-2 diabetes (T2D) and its complication. T2D, which used to be referred to as adult-onset or non-insulin-dependent diabetes, accounts for over 90–95% of all diabetes; T2D is a complex metabolic disorder essentially characterized by alterations in lipid metabolism, insulin resistance, and pancreatic β -cell dysfunction [5]. Unfortunately, there are no effective treatments available for T2D, although there have been many developments in the therapeutic arena [6]. Hence there is an urgent need to develop new preventative and/or therapeutic strategies to combat T2D.

Over the past three decades, NO has emerged as a central regulator of energy metabolism and body composition. NO bioavailability is decreased in animal models of diet-induced obesity and in obese and insulin-resistant patients, and increasing NO output has remarkable effects on obesity and insulin resistance [7]. This volume is a collection of reviews dealing with *The Role of Nitric Oxide in Type 2 Diabetes*. These reviews provide a unique overview of NO signaling, pointing out key areas for more detailed research. We hope that the breadth of the topics covered in this volume will provide new perspectives and help to stimulate research towards unanswered questions.

Chapter 1 is an overview of the pathophysiology of T2D by Drs. Ghasemi and Kashfi entitled, “Pathophysiology of Type 2 Diabetes: A General Overview of Glucose and Insulin Homeostasis”. A better understanding of the pathophysiology of T2D provides an opportunity for revising the current therapeutic modalities, from a primary glycemic control to a pathophysiological-based approach. This chapter provides essential information on glucose homeostasis and the pathophysiology of T2D. Chapter 2 by Drs. Ghasemi and Kashfi is entitled “Nitric oxide: A Brief History of Discovery and Timeline of its Research.” This chapter highlights the discovery of NO in mammals and its role as a signaling molecule. The overview describes the chronological development of NO, emphasizing the events in the last two decades of the 20th century. Chapter 3 is a review by Drs. Bahadoran, Carlström, Mirmiran, and Ghasemi entitled, “Impaired Nitric Oxide Metabolism in Type 2 Diabetes: At a Glance”. Abnormal NO metabolism is associated with the development of insulin resistance and T2D, which in turn can lead to impaired NO homeostasis. The concept of NO deficiency is supported by results from human studies on polymorphisms of endothelial NO synthase (eNOS) gene, animal knockout models for NO synthase isoforms (N.O.S.s), and pharmacological inhibitors of N.O.S. This chapter focuses on the role of impaired NO metabolism in T2D.

Chapter 4 by Drs. Bahadoran, Carlström, Mirmiran, and Ghasemi is entitled “Asymmetrical Dimethyl Arginine, Nitric Oxide, and Type 2 Diabetes”. Asymmetric dimethylarginine (ADMA) is an endogenous competitive inhibitor of nitric oxide synthases. Over-production leads to decreased NO bioavailability and diabetes complications, including cardiovascular diseases, nephropathy, and retinopathy, with increased mortality risk. This chapter discusses how disrupted ADMA metabolism contributes to the development of T2D and its complications. Chapter 5 is a contribution by Drs. Bahadoran, González-Muniesa, Mirmiran, and Ghasemi is entitled, “Nitric Oxide-Related Oral Microbiota Dysbiosis in Type 2 Diabetes”. This chapter gives an overview of oral microbiota dysbiosis in T2D, focusing on nitrate-reducing bacteria and their metabolic activity.

Chapter 6, entitled “Nitric oxide and Type 2 Diabetes: Lessons from Genetic Studies”, is a contribution by Drs. Bahadoran, Mirmiran, Carlström, and Ghasemi. They discuss current genetic data linking NO metabolism to metabolic disorders, especially insulin resistance and T2D. Chapter 7 is a contribution by Dr. Afzali, Miss Ranjbar, and Drs. Kashfi and Ghasemi entitled, “Role of Nitric Oxide in Diabetic Wound Healing.” NO deficiency is an important mechanism responsible for poor healing in diabetic wounds. The beneficial effects of NO in wound healing are related to its antibacterial properties, regulation of inflammatory response, stimulation of proliferation, differentiation of keratinocytes and fibroblasts, and promotion of angiogenesis and collagen deposition. In this chapter, the function of NO in diabetic wound healing and the possible therapeutic significance of NO in the treatment of diabetic wounds are discussed.

Chapter 8 is entitled “Role of Nitric Oxide in Type 2 Diabetes-Induced Osteoporosis” by Drs. Yousefzadeh, Jeddi, Kashfi, and Ghasemi. Diabetoporosis, which is osteoporosis in type 2 diabetic patients, contributes to and aggravates osteoporotic fractures. Decreased eNOS-derived NO and higher iNOS-derived NO are some of the critical mechanisms in diabetoporosis. This chapter closely examines the role of NO in diabetoporosis. Chapter 9 by Drs. Bahadoran, Mirmiran, Kashfi, and Ghasemi is entitled, “Hyperuricemia, Type 2 Diabetes and Insulin Resistance: Role of Nitric Oxide”. Hyperuricemia is a risk factor for developing hypertension, cardiovascular diseases, chronic kidney disease, and T2D. It leads to the development of systemic insulin resistance, impaired NO and glucose metabolism, with induction of inflammation and oxidative stress. This chapter highlights the mediatory role of NO metabolism on hyperuricemia-induced dysglycemia and insulin resistance. Chapter 10 is entitled “Therapeutic management of type 2 diabetes: The nitric oxide axis,” by Ms. Ranjbar, O’Connor, and Dr. Kashfi. Current drugs approved for the management of T2D include biguanides, thiazolidinediones, sulfonylureas, meglitinides, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, alpha-glucosidase inhibitors, and sodium-glucose co-transporter 2 (SGLT2) inhibitors. In this chapter, the authors discuss these drugs, examine their mechanism of action, and present evidence that these drugs directly or indirectly modulate NO metabolism.

In Chapter 11, “Brain Insulin Resistance, Nitric Oxide and Alzheimer’s Disease Pathology,” Drs. Pei, Lee, Khan, and Wang discuss the role of NO availability in brain insulin resistance in dementia associated with Alzheimer’s disease. Chapter 12 by Drs. Mirmiran, Bahadoran, Kashfi, and Ghasemi, and is entitled “Arginine, Nitric Oxide and Type 2 Diabetes”. In this chapter, the authors provide an overview of the potential efficacy of L-arginine (Arg) as an NO precursor and its effects on glucose and insulin homeostasis and diabetes-induced cardiovascular complications. Chapter 13 is also by Drs. Mirmiran, Bahadoran, Kashfi, and Ghasemi and is entitled “Citrulline, Nitric Oxide and Type 2 Diabetes”. L-Citrulline (Cit) is a precursor of Arg and is involved in NO synthesis. Oral ingestion of Cit effectively elevates

total Arg flux and promotes NO production. In this chapter, the authors discuss the potential use of Cit as an effective anti-diabetic agent.

Recent data suggest the utility of the nitrate-nitrite-nitric oxide (NO₃-NO₂-NO) pathway in treating T2D. Supplementation with inorganic NO₃-NO₂ in animal models of T2D resulted in improved hyperglycemia, insulin sensitivity, and glucose tolerance [8 - 10]. However, the efficacy of NO₃-NO₂ supplementation on glucose and insulin homeostasis in humans is unproven. In chapter 14, entitled “Nitrate, Nitrite, and Type 2 Diabetes”, Drs. Bahadoran, Mirmiran, Kashfi, and Ghasemi review the animal experiments and human clinical trials, addressing the potential effects of inorganic NO₃/NO₂ on glucose and insulin homeostasis in T2D. They also provide several plausible scenarios to address the challenge of lost-in-translation of beneficial effects of inorganic NO₃ and NO₂ from bench to bedside.

The final chapter of this book, chapter 15, is a review by Drs. Bahadoran, Mirmiran, Bahmani, and Ghasemi entitled, “Potential Applications of Nitric Oxide Donors in Type 2 Diabetes”. NO-donors have increasingly been studied as promising therapeutic agents for insulin resistance and T2D. This chapter reviews the effects of sodium nitroprusside, S-nitrosothiols, and N-diazeniumdiolates on glucose and insulin homeostasis.

We hope that the breadth of topics covered in this volume will provide the readers with new perspectives, give some food for thought, and stimulate more research into major unanswered questions.

REFERENCES

- [1] Culotta E, Koshland DE, Jr. NO news is good news. *Science* 1992; 258(5090): 1862-5. [http://dx.doi.org/10.1126/science.1361684] [PMID: 1361684]
- [2] Hales CM, Fryar CD, Carroll MD, Freedman DS, Ogden CL. Trends in Obesity and Severe Obesity Prevalence in US Youth and Adults by Sex and Age, 2007-2008 to 2015-2016. *JAMA* 2018; 319(16): 1723-5. [http://dx.doi.org/10.1001/jama.2018.3060] [PMID: 29570750]
- [3] Alemán JO, Eusebi LH, Ricciardiello L, Patidar K, Sanyal AJ, Holt PR. Mechanisms of obesity-induced gastrointestinal neoplasia. *Gastroenterology* 2014; 146(2): 357-73. [http://dx.doi.org/10.1053/j.gastro.2013.11.051] [PMID: 24315827]
- [4] Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB. Years of life lost due to obesity. *JAMA* 2003; 289(2): 187-93. [http://dx.doi.org/10.1001/jama.289.2.187] [PMID: 12517229]
- [5] Podell BK, Ackart DF, Richardson MA, DiLisio JE, Pulford B, Basaraba RJ. A model of type 2 diabetes in the guinea pig using sequential diet-induced glucose intolerance and streptozotocin treatment. *Dis Model Mech* 2017; 10(2)dmm.025593 [http://dx.doi.org/10.1242/dmm.025593] [PMID: 28093504]
- [6] Srinivasan K, Ramarao P. Animal models in type 2 diabetes research: an overview. *Indian J Med Res* 2007; 125(3): 451-72. [PMID: 17496368]
- [7] Sansbury BE, Hill BG. Regulation of obesity and insulin resistance by nitric oxide. *Free Radic Biol Med* 2014; 73: 383-99. [http://dx.doi.org/10.1016/j.freeradbiomed.2014.05.016] [PMID: 24878261]

- [8] Gheibi S, Bakhtiarzadeh F, Jeddi S, Farrokhfall K, Zardooz H, Ghasemi A. Nitrite increases glucose-stimulated insulin secretion and islet insulin content in obese type 2 diabetic male rats. *Nitric Oxide* 2017; 64: 39-51.
[<http://dx.doi.org/10.1016/j.niox.2017.01.003>] [PMID: 28089828]
- [9] Ghasemi A, Jeddi S. Anti-obesity and anti-diabetic effects of nitrate and nitrite. *Nitric Oxide* 2017; 70: 9-24.
[<http://dx.doi.org/10.1016/j.niox.2017.08.003>] [PMID: 28804022]
- [10] Bahadoran Z, Mirmiran P, Ghasemi A. Role of Nitric Oxide in Insulin Secretion and Glucose Metabolism. *Trends Endocrinol Metab* 2020; 31(2): 118-30.
[<http://dx.doi.org/10.1016/j.tem.2019.10.001>] [PMID: 31690508]

Khosrow Kashfi

Department of Molecular, Cellular and Biomedical Sciences,
Sophie Davis School of Biomedical Education,
Graduate Program in Biology,
City University of New York School of Medicine,
New York, NY 10031, U.S.A

Asghar Ghasemi

Endocrine Physiology Research Center,
Research Institute for Endocrine Sciences,
Shahid Beheshti University of Medical Sciences,
Tehran, Iran

Zahra Bahadoran

Nutrition and Endocrine Research Center,
Research Institute for Endocrine Sciences,
Shahid Beheshti University of Medical Sciences,
Tehran, Iran

List of Contributors

- Asghar Ghasemi** Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- Amber Khan** Department of Molecular, Cellular and Biomedical Sciences, City University of New York School of Medicine, 160 Convent Avenue, New York, New York 10031, USA
Department of Biology, Neuroscience Program, Graduate School of The City University of New York, 365 Fifth Avenue, New York, New York 10061, USA
- Hamideh Afzali** Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- Hoau-Yan Wang** Department of Molecular, Cellular and Biomedical Sciences, City University of New York School of Medicine, 160 Convent Avenue, New York, New York 10031, USA
Department of Biology, Neuroscience Program, Graduate School of The City University of New York, 365 Fifth Avenue, New York, New York 10061, USA
- Jennifer L. O'Connor** Department of Molecular, Cellular, and Biomedical Sciences, Sophie Davis School of Biomedical Education, City University of New York School of Medicine, New York, NY, USA
Department of Chemistry and Physics, State University of New York at Old Westbury, Old Westbury, NY, USA
- Khosrow Kashfi** Department of Molecular, Cellular and Biomedical Sciences, City University of New York School of Medicine, Sophie Davis School of Biomedical Education, New York, USA
- Mattias Carlström** Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden
- Mehrnoosh Bahmani** Ontario College of Pharmacist, University of Waterloo School of Pharmacy Alumni, Waterloo, Ontario, Canada
- Nasibeh Yousefzadeh** Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- Parvin Mirmiran** Department of Clinical Nutrition and Human Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- Pedro González-Muniesa** Department of Nutrition, Food Science and Physiology, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain
Center for Nutrition Research; School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain
CIBER Physiopathology of Obesity and Nutrition (CIBERObn, Carlos III Health Institute (ISCIII), Spain,
IDISNA, Navarra Institute for Health Research, Pamplona, Spain
- Sajad Jeddi** Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

viii

Tara Ranjbar

Department of Molecular, Cellular, and Biomedical Sciences, Sophie Davis School of Biomedical Education, City University of New York School of Medicine, New York, NY 10031, USA

Zahra Bahadoran

Nutrition and Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Zhe Pei

Department of Molecular, Cellular and Biomedical Sciences, City University of New York School of Medicine, 160 Convent Avenue, New York, New York 10031, USA

CHAPTER 1

Pathophysiology of Type 2 Diabetes: A General Overview of Glucose and Insulin Homeostasis

Asghar Ghasemi^{1,*} and Khosrow Kashfi²

¹ Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

² Department of Molecular, Cellular and Biomedical Sciences, Sophie Davis School of Biomedical Education, City University of New York School of Medicine, New York, NY 10031, USA

Abstract: The prevalence of diabetes is increasing worldwide, and this disease has a tremendous financial burden on most countries. Major types of diabetes are type 1 diabetes and type 2 diabetes (T2D); T2D accounts for 90-95% of all diabetic cases. For better management of diabetes, we need to have a better understanding of its pathophysiology. This chapter provides an overview of glucose homeostasis and the underlying pathophysiology of T2D.

Keywords: β -Cell Dysfunction, Glucose Homeostasis, Insulin, Impaired Glucose Tolerance, Insulin Resistance, Insulin Signaling Pathways, Impaired Fasting Glycemia, Type 2 Diabetes.

INTRODUCTION

Diabetes is the largest epidemic in human history [1], and there is currently a rapid-growing diabetes pandemic [2]. From 1980 to 2014, the total number of subjects with diabetes has quadrupled [3, 4]. More than 70% of global mortality is attributed to non-communicable diseases, including diabetes [5, 6]. Diabetes is the ninth leading cause of death [7], and in 2017, it caused one death every eight seconds (2.1 and 1.8 million in women and men aged 20–79 years, respectively) [2]. On average, healthcare expenditures for diabetic subjects are two-fold higher than those without diabetes [2]; in addition, approximately 79.4% of people with diabetes live in low- and middle-income countries [8]. Hyperglycemia is the third leading modifiable cause of death after high blood pressure and tobacco use [3]. A better understanding of the pathophysiology of type 2 diabetes (T2D) provides

* Corresponding author **Asghar Ghasemi:** Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Ghasemi@endocrine.ac.ir., No. 24, Erabi Street, Velenjak, Tehran, Iran; Phone: +98 21 22409309; Fax: +98 21 22416264.

an opportunity for revising the current therapeutic modalities in the management of T2D, from a primary glycemic control to a pathophysiological-based approach. This chapter provides essential information on glucose homeostasis and the pathophysiology of T2D.

EPIDEMIOLOGY OF DIABETES

Amongst adults aged 20–79 years, the worldwide prevalence of diabetes in 2019, was 9.3% (9.0% in women and 9.6% in men), and unfortunately, this is expected to rise to 10.2% (578.4 million) and 10.9% (700.2 million) in 2030 and 2045, respectively [8]. There is considerable geographical/cultural heterogeneity relating to the incidence of diabetes. For example, the crude incidence of diabetes ranges from 2.9 per 1000 population in France to 23.5 per 1000 population in the Pima Indians of the United States [9]. Also, the incidence of diabetes increases with age because of decreased ability of the β -cells to compensate for insulin resistance [10]. Major types of diabetes are type 1 and type 2. Type 1 diabetes accounts for 5-10% of all diabetes [2], and patients require insulin therapy. Type 2 diabetes, which used to be referred to as adult-onset or non-insulin-dependent diabetes, accounts for over 90–95% of all diabetes [11]; T2D is a complex metabolic disorder essentially characterized by alterations in lipid metabolism, insulin resistance, and pancreatic β -cell dysfunction [12, 13].

Worldwide, the prevalence of prediabetes is also increasing [14]. Prediabetes is defined as a state of higher than normal glycemia that does not meet the established criteria for diabetes diagnosis and includes subjects with impaired fasting glycemia (IFG), impaired glucose tolerance (IGT), or both [11]. Prediabetes can predict the risk of developing diabetes [11, 15], and in some subjects, it can be alleviated by lifestyle modifications or pharmacological interventions, such as metformin administration [16]. Table 1 summarizes some statistical data about diabetes according to the International Diabetes Federation (IDF) report.

Table 1. Diabetes: Global statistics overview*.

	Year		
	2019	2030	2045†
Prevalence of diabetes % (million)	9.3% (463.0)	10.2% (578.4)	10.9% (700.2)
Prevalence of impaired glucose tolerance % (million)	7.5% (373.9)	8.0% (453.8)	8.6% (548.4)
Attributable all-cause mortality to diabetes (million)	4.2	-	-

(Table 1) cont....

Healthcare expenditure for diabetes (USD billion)	Year		
		760.3	824.7

* According to the International Diabetes Federation (IDF) [8]
† Estimated values; total world population was 7.7 billion in 2019 and is estimated to be 8.6 and 9.5 billion in 2030 and 2045, of whom 5.0, 5.7, and 6.4 billion are aged 20-79 years.

DIAGNOSIS OF DIABETES

Diabetes is diagnosed using glucose-based criteria, *i.e.*, fasting plasma glucose (FPG) levels or 2-h plasma glucose (2-hPG) levels during a 75-g oral glucose tolerance test; hemoglobin A1c (HbA1C) levels are also used as an indicator [11, 17]. Table 2 provides diagnostic criteria for T2D according to the World Health Organization (WHO) and the American Diabetes Association (ADA).

Table 2. Diagnostic criteria of diabetes*.

		ADA	WHO
Diabetes		FPG \geq 126 mg/dL or 2-hPG \geq 200 mg/dL or HbA1C \geq 6.5%	FPG \geq 126 mg/dL or 2-hPG \geq 200 mg/dL or HbA1C \geq 6.5%
Prediabetes	IFG	FPG: 100–125 mg/dL	FPG: 110–125 mg/dL
	IGT	2-hPG: 140–199 mg/dL	2-hPG: 140–199 mg/dL
	HbA1C	5.6–6.5%	–

* According to World Health Organization (WHO) and American Diabetes Association (ADA) criteria [11, 17].
2-hPG, 2-h plasma glucose; FPG, fasting plasma glucose; HbA1C, glycated hemoglobin; IFG, impaired fasting glucose; IGT, impaired glucose tolerance.
To convert glucose concentration from mg/dL multiplied by 0.05551.

GLUCOSE HOMEOSTASIS

Maintaining blood glucose concentrations within a physiologic range, either in a fasted state or excess nutrient availability, is essential for keeping normal bodily functions [18]. This critical homeostasis is achieved through a complex network involving hormones and neuropeptides released mainly from the brain, pancreas, liver, intestine, adipose tissue, and skeletal muscle [19].

Nutrient sensing and hormonal signaling regulate glucose homeostasis, controlling tissue-specific glucose utilization and production [18]. With the use of homeostatic mechanisms, the body protects itself against either hyperglycemia (and its complications, *i.e.*, retinopathy, neuropathy, nephropathy, premature atherosclerosis, diabetic ketoacidosis, and hyperosmolar hyperglycemic state) or

CHAPTER 2

Nitric oxide: A Brief History of Discovery and Timeline of its Research

Asghar Ghasemi^{1,*} and Khosrow Kashfi²

¹ Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

² Department of Molecular, Cellular and Biomedical Sciences, Sophie Davis School of Biomedical Education, City University of New York School of Medicine, New York, NY10031, USA

Abstract: Nitric oxide (NO) plays a critical role in many physiological and pathological functions in the human body. Following the discovery in 1986-1987 that endothelium-derived relaxing factor (EDRF) is NO, the number of NO-based publications within all fields of medicine has increased exponentially. This report provides a brief historical view of NO-based research, emphasizing the events in the last two decades of the 20th century.

Keywords: Cyclic Guanosine Monophosphate, Endothelial Nitric Oxide Synthase, Endothelium-Derived Relaxing Factor, History, Inducible Nitric Oxide Synthase, Nitric Oxide, Neural Nitric Oxide Synthase, Nitric Oxide Deficiency, Nitric Oxide Donating Agents, Wall Saltpeter.

INTRODUCTION

Humans have a long history of using nitrogen-containing substances. About 5000 years ago, “wall saltpeter” [Ca(NO₃)₂] or “niter” (KNO₃) were used to preserve foods [1, 2]; in addition, sublingual KNO₃ was used for treating angina about 1000 years ago [3]. Research on nitric oxide (NO) functions began in the late 1970s to the early 1980s. It bloomed in 1998 when the Nobel Prize in Physiology or Medicine was awarded to Robert F. Furchgott, Louis J. Ignarro, and Ferid Murad “for their discoveries concerning NO as a signaling molecule in the cardiovascular system” [4].

Nitric oxide is a free radical gas [5]. It has been called an ephemeral substance [6], a pharmacologic smart bomb [5], a powerful queen of communication and

* Corresponding author Asghar Ghasemi: Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran; No. 24, Erabi Street, Velenjak, Tehran, Iran; Phone: +98 21 22409309; Fax: +98 21 22416264, Email: Ghasemi@endocrine.ac.ir

defense [7], and the most ubiquitous intercellular signaling molecule [8]. Nowadays, we accept that NO is involved in the homeostasis of almost every physiological system in the human body [9]. In addition, active research is ongoing in which NO is a target molecule for disease treatment. Thus, historicizing science acknowledges the pioneers and helps us better conceptualize the issues. This chapter provides a brief historical view of NO-based research.

HISTORY OF NO FIELD

Table 1 presents chronological progress in NO research, and (Fig. 1) highlights the main events. According to a paper by Ignarro, the NO field study was launched by the Murad group in the 1970s [10]. However, as Furchgott had discussed, the story of NO began in 1953 when it was found that acetylcholine (ACh), which was known to be a vasodilator in the whole animal, caused contraction of aortic strips of the rabbit aorta [11]. However, in an experiment conducted in 1978, it was accidentally realized that ACh partially relaxes norepinephrine-induced precontracted rabbit aorta [11].

In 1980, Furchgott and Zawadzki reported that ACh, *via* its muscarinic receptors, stimulates endothelial cells to release a substance or substances, which cause(s) relaxation of vascular smooth muscle cells [12]. The substance was initially named the Furchgott Factor to distinguish it from other endothelium-dependent relaxing factors [13]. ACh-induced endothelium-dependent relaxation of vascular smooth muscle was also observed in other vessels [12] and considered a principal mechanism of the vasodilatory effect of muscarinic agonists [14]. Cyclooxygenase inhibitors did not affect ACh-induced endothelium-dependent relaxation of the vascular smooth muscles, leading to this hypothesis that activating muscarinic receptors by ACh releases a non-prostanoid substance from the endothelial cells that diffuses to and relaxes vascular smooth muscle cells [11]. Besides, the sandwich procedure, in which endothelium-denuded transverse strips of the aorta and endothelium-intact longitudinal strips mounted together in clips with intimal surface apposed, provides direct evidence for the hypothesis as at this condition, ACh-induced relaxation of the muscle was restored [11, 12].

In 1981, it was found that hydroquinone, a free radical quencher, inhibits ACh-induced relaxation suggesting that the relaxing factor may be a free radical [14]. In the same year (1981), it was found that there are other endothelium-dependent relaxing agents, including a Ca^{2+} ionophore (A23187) [14], which suggested a central role for calcium in the release or synthesis of the relaxing factor [11]. For the details of the first reports of substances that elicited endothelium-dependent relaxation, interested readers are referred to Furchgott and Vanhoutte [15]. Regarding the positive association between increased cyclic guanosine

monophosphate (cGMP) and smooth muscle relaxation, in 1981, Furchgott speculated that the relaxing factor relaxes vascular smooth muscle *via* increasing cGMP; this hypothesis was true [11].

In 1982, the non-prostanoid substance involved in vascular smooth muscle relaxation was referred to as endothelium-derived relaxing factor (EDRF) by the Furchgott group [11, 16, 17]. In 1987, Ignarro and colleagues reported that based on direct chemical and indirect pharmacological evidence, EDRF closely resembles NO [18]. According to Furchgott, based on several works, the concept that EDRF is NO was independently proposed by him and Ignarro in 1986 in a symposium; papers of this symposium were published in 1988 [11]. One year after the 1986 symposium, in 1987, three groups, including Ignarro *et al.* [19], Moncada *et al.* [20], and Furchgott *et al.* [11], reported that EDRF is NO. According to a recent review by Lancaster, investigations in parallel lines of cancer/immune, cardiovascular, and the nervous system converged in 1986-1988, which led to NO's discovery [21].

In 1988, *L*-arginine was identified as the endogenous substrate for NO synthesis by the Moncada group [22] and others [23]. This discovery was based on previous reports highlighting that activated macrophages generate nitrite and nitrate from *L*-arginine [6]. In 1990, Bredt and Snyder isolated and purified NO synthase (they named it NO synthetase) from rat cerebellum as a calmodulin-requiring enzyme [24]; following neuronal NOS (nNOS) isolation, inducible NOS (iNOS), and endothelial NOS (eNOS) were also isolated in 1991 [25, 26]. NOS isoforms originally were named after the tissues in which they were first identified [6, 27]. However, because both eNOS and nNOS have inducible forms and iNOS is also constitutively expressed in some tissues, nNOS, iNOS and eNOS are currently referred to as NOS-I, NOS-II, and NOS-III, respectively, according to the order in which they were first cloned [28]. NO production *via* the *L*-arginine-NO pathway occurs in almost every cell in the human body [29].

In 1992, Science magazine selected NO as the molecule of the year [30], and it was discovered that S-nitrosylation is a cellular regulatory mechanism of NO action [31]. In 1994, NOS-independent NO generation was reported in the stomach [32, 33]; this suggested an alternative or backup system besides the classical *L*-arginine pathway for sufficient NO generation, particularly during hypoxia [34]. In 1998, Pfizer company introduced sildenafil (Viagra®) for managing erectile dysfunction in men [10, 35]; sildenafil inhibits phosphodiesterase 5A (PDE5A) and increases intracellular cGMP [28]. In 1999, inhaled NO was approved by the U.S. Food and Drug Administration (FDA) for treating infants with persistent pulmonary hypertension [36, 37]. In 2001, the first report of enzymatic denitrosation and nitrosothiols' regulation by NO was

CHAPTER 3

Impaired Nitric Oxide Metabolism in Type 2 Diabetes: At a Glance

Zahra Bahadoran¹, Mattias Carlström², Parvin Mirmiran³ and Asghar Ghasemi^{4,*}

¹ Nutrition and Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

² Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden

³ Department of Clinical Nutrition and Human Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran

⁴ Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract: Abnormal nitric oxide (NO) metabolism has been associated with the development of insulin resistance and type 2 diabetes (T2D). The concept of NO deficiency is supported by human studies on polymorphisms of endothelial NO synthase (eNOS) gene, animal knockout models for NO synthase isoforms (NOSs), and pharmacological evidence, showing detrimental effects of NOS inhibitors and salutary effects of NO donors on carbohydrate metabolism. On the other hand, T2D and insulin resistance may impair NO homeostasis due to hyperglycemia, oxidative stress, and inflammation. Reduced production of NO [*i.e.*, impaired *L*-arginine-NOS pathway and function of the nitrate (NO₃)-nitrite (NO₂)-NO pathway], impaired NO transport within the circulation and delivery to target cells, as well as disrupted NO signaling (*e.g.*, via oxidative-induced NO quenching, and impaired NO-cGMP signaling pathway) can all lead to a reduced NO bioactivity in T2D. This chapter focuses on the role of impaired NO metabolism in T2D.

Keywords: Dysglycemia, Endothelial Nitric Oxide Synthase, Glucose Metabolism, Insulin Resistance, Inducible Nitric Oxide Synthase, Neural Nitric Oxide Synthase, Nitric Oxide, Nitric Oxide Deficiency, Type 2 Diabetes.

* **Corresponding author Asghar Ghasemi:** Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran; No. 24, Erabi Street, Velenjak, Tehran, Iran; Phone: +98 21 22409309; Fax: +98 21 22416264, Email: Ghasemi@endocrine.ac.ir

INTRODUCTION

Nitric oxide (NO), commonly known as a unique biological free radical and signaling molecule with multiple functions [1, 2], is now considered an endocrine hormone [3] critically involved in whole-body glucose and insulin metabolism [4]. Fig. (1) illustrates two main pathways of NO production [the *L*-arginine-NO synthase (NOS) pathway and the nitrate (NO₃)-nitrite (NO₂)-NO pathway] and its metabolism.




Fig. (1). Pathways of nitric oxide (NO) production and metabolism. Two main pathways of NO production are the *L*-arginine-NO synthase (NOS) pathway and the nitrate (NO₃)-nitrite (NO₂)-NO pathway. *L*-arginine is provided by either exogenous (dietary intake, about 4000-6000 mg/day) or endogenous (de novo synthesis from citrulline and turnover of proteins) sources. This pathway is responsible for producing about 1000 μmol/day NO. Inorganic NO₃ and NO₂, provided either from dietary sources or endogenous NO metabolism, are used as substrates for non-enzymatic endogenous NO generation. This pathway is estimated to produce about 100 μmol/day NO. The source of the Fig. is (5), Quantitative aspects of nitric oxide production from nitrate and nitrite, EXCLI Journal, 2022, 21: 470-486.

Impaired NO bioavailability is a common state in metabolic disorders, including type 2 diabetes (T2D), that is mainly attributed to decreased endothelial NO synthase (eNOS) expression or activity or by NO scavenging in conditions with excessive production of reactive oxygen species (ROS) [6, 7]. A bilateral cause-and-consequence relation exists between impaired NO metabolism and the development and progression of T2D (Fig. 2).




Fig. (2). A proposed cause-and-effect and bilateral relationship between impaired nitric oxide (NO) metabolism and development of insulin resistance and type 2 diabetes (T2D). AGE, advanced glycation end product; cNOS, constitutive nitric oxide synthase; NO₃, nitrate; NO₂, nitrite; RAGE, receptor for AGE. Created with Biorender.com.

The critical role of NO in regulating glucose and insulin homeostasis is supported by experimental studies using genetically modified mice, either eNOS knockouts or eNOS over-expressed mice. Impaired glucose and insulin metabolism, as evident from hyperglycemia, hyperinsulinemia, insulin resistance, and glucose intolerance, occurs in homozygous [8 - 11] and heterozygous eNOS knockout animals [12], whereas overexpression of eNOS prevents diet-induced hyperinsulinemia [13, 14]. In contrast, overexpression of inducible NOS (iNOS) and hence the production of very high levels of NO is associated with the development of skeletal muscle insulin resistance [15], hepatic insulin resistance, hyperglycemia, and hyperinsulinemia [16]. iNOS-deficient mice compared to wild type, did not show metabolic dysfunctions induced by the high-fat diet (HFD) and displayed normal glucose tolerance, insulin sensitivity, and insulin-stimulated glucose uptake in the skeletal muscle [17]. HFD increased iNOS mRNA expression by 2 to 4-fold in skeletal muscle [type I (soleus), type II-a (extensor digitorum longus, EDL), and type II-b (tibialis) fibers] and adipose tissue of wild-type mice. In contrast, obese *Nos2*^{+/-} mice had normal insulin levels, glucose tolerance, and normal skeletal muscle glucose uptake than lean *Nos2*^{+/-} or wild-type mice under a standard diet [17]. This evidence indicates that targeted

CHAPTER 4

Asymmetrical Dimethyl Arginine, Nitric Oxide, and Type 2 Diabetes

Zahra Bahadoran¹, Mattias Carlström², Parvin Mirmiran³ and Asghar Ghasemi^{4,*}

¹ Nutrition and Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

² Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden

³ Department of Clinical Nutrition and Human Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran

⁴ Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract: Asymmetric dimethylarginine (ADMA), an endogenous competitive inhibitor of nitric oxide (NO) synthase (NOS) isoenzymes, can substantially inhibit vascular NO production at concentrations that are observed in pathophysiological conditions. Over-production of ADMA (*via* overexpression and/or activity of class 1 of the protein arginine methyltransferases, PRMT-1) alongside decreased catabolism (due to decreased expression and/or activity of dimethylarginine dimethylaminohydrolase, DDAH) in type 2 diabetes (T2D) and insulin resistance results in increased circulatory and intracellular ADMA levels. Such pathological elevated ADMA levels lead to a decreased NO bioavailability and the development of diabetes complications, including cardiovascular diseases, nephropathy, and retinopathy; elevated ADMA levels also increase the mortality risk in these patients. Here, we discuss current documents indicating how disrupted ADMA metabolism contributes to the development of T2D and its complications. The role of other endogenous methylarginines, *i.e.*, NG-monomethyl-*L*-arginine (*L*-NMMA) and NG, NG'-dimethyl-*L*-arginine (SDMA) on NO production and T2D are also discussed.

Keywords: Asymmetric Dimethylarginine, Cationic Amino Acid Transporter, *L*-Citrulline, Dimethylarginine, Dimethylaminohydrolase, Endothelial Nitric Oxide Synthase, *L*-Arginine, Nitric Oxide, N^G-Monomethyl-*L*-Arginine, N^G, N^{G'}-Dimethyl-*L*-Arginine, Protein Arginine Methyltransferases, Type 2 Diabetes.

* Corresponding author Asghar Ghasemi: Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran; No. 24, Erabi Street, Velenjak, Tehran, Iran; Phone: +98 21 22409309; Fax: +98 21 22416264, Email: Ghasemi@endocrine.ac.ir

INTRODUCTION

Asymmetric dimethylarginine (N^G , N^G -dimethyl-*L*-arginine, ADMA), a naturally occurring amino acid, is synthesized upon hydrolysis of methylated cellular proteins and circulates within the plasma [1, 2]. ADMA and other methylarginines were isolated from human urine in 1970 by Kakimoto *et al.* [3]. ADMA is an endogenous inhibitor of nitric oxide (NO) synthase (NOS) isoenzymes [1, 2]. The first report introducing ADMA as an endogenous inhibitor of NOS goes back to 1992, when Vallance *et al.* described that accumulation of intracellular ADMA decreases NO availability and contributes to the development of hypertension and renal dysfunction [4]. Beyond inhibition of NOS activity, ADMA may reduce NOS expression and cause uncoupling of NOS in endothelial cells leading to increased superoxide generation and subsequent oxidative stress [5, 6].

In healthy humans, the mean plasma level of ADMA is ~ 0.5 - 0.7 μM [7, 8], with a range of 0.22 to 0.79 μM [9]. Several human studies reported increased plasma ADMA levels in pathologic conditions, including hypertension, kidney diseases, hypercholesterolemia, atherosclerosis, type 2 diabetes (T2D), and chronic heart failure [10 - 13]. ADMA has also received more clinical attention since its elevated level is an independent risk factor for cardiometabolic diseases [14, 15]. Elevated ADMA level is an independent predictor of cardiovascular disease [relative risk (RR)= 1.42 , 95% CI= 1.29 - 1.56], coronary heart disease (RR= 1.39 , 95% CI= 1.19 - 1.62), stroke (RR= 1.60 , 95% CI= 1.33 - 1.91) [15], and all-cause mortality (RR= 1.31 , 95% CI= 1.13 - 1.53) [16].

Here, we summarize ADMA metabolism and the importance of the ADMA-dimethylarginine dimethylaminohydrolase (DDAH) pathway on whole-body NO synthesis and bioavailability. Then we discuss current reports regarding how the disrupted ADMA-DDAH pathway can contribute to the development of T2D and its complications. We also focused on the potential role of other endogenous methylarginines, *i.e.*, N^G -monomethyl-*L*-arginine (*L*-NMMA) and N^G , N^G -dimethyl-*L*-arginine or symmetric dimethylarginine (SDMA) on NO production and development of T2D and its complications.

ADMA BIOSYNTHESIS AND METABOLISM

ADMA is released upon hydrolysis of post-translationally methylated intracellular proteins by protein arginine methyltransferases (PRMTs). Methylation of *L*-arginine (Arg) residues in cellular proteins is a post-translational modification, transferring 1 or 2 methyl groups to the guanidine nitrogens of Arg [1, 2, 17]. In mammals, two PRMT isoenzymes are identified, type I (PRMT 1, 3, 4, 6, and 8) and type II (PRMT 5, 7, and F-box only protein 11, FBXO11) [18]. The PRMT type I is responsible for about 85% of total protein Arg methylation activity [19].

Each day about 300 μmol ADMA is constitutively synthesized during the turnover of methylated Arg residues in proteins [1, 20]. About 80-90% of ADMA is metabolized by the dimethylarginine dimethylaminohydrolase (DDAH) into *L*-citrulline (Cit) and dimethylamine, and a small part (10-20%) is metabolized by aminotransferase and excreted by the kidneys [1, 2, 21].

About 250 μmol of ADMA is daily degraded by DDAH [22], and urinary excretion of ADMA over a 24-h period is estimated to be 13.5 ± 3.1 mg (~ 65 μmol per 24-h) in healthy adults [4]. In humans, red blood cells (RBCs) play a critical role in the synthesis and storage of ADMA; there is fast bidirectional traffic of ADMA across the plasma membrane of the RBCs that leads to equilibrium between intra- and extracellular ADMA [23].

In humans, two isoforms of DDAH are found: DDAH-1 and DDAH-2; DDAH-1 is the predominant form in the liver and kidney tubules [24] as well as in the brain at sites of neural NOS (nNOS) expression [25]. About 70% of ADMA is metabolized in the kidney and liver *via* DDAH-1 [26]. DDAH-1 activity in the kidney and liver is responsible for the metabolism of excessive circulating ADMA [27]. Although DDAH-1 regulates the degradation of ADMA in neuronal tissues, recent data indicate that it is the major isomer regulating systemic ADMA and cardiovascular NO bioavailability [28, 29]. DDAH-2 predominates in tissues expressing endothelial NOS (eNOS) (*e.g.*, heart, vascular endothelium, and smooth muscle cells) and inducible NOS (iNOS) (*e.g.*, immune tissues) [24, 30, 31]. DDAH-2 is a major player in regulating ADMA levels in the heart and vessels [28, 29].

The K_m values of DDAH-1 and DDAH-2 for ADMA are higher than their intracellular concentrations [31]. K_m value of DDAH-1 for ADMA is 170 μM in humans, and K_{cat} is 1.66 $\mu\text{mol/L/min}$ [32]. K_m value of DDAH-2 for ADMA is 16 μM and V_{max} value is 4.8 nmol/mg/min [33]. The apparent rate of ADMA metabolism for DDAH-2 is ~ 70 times less than that of DDAH-1 [33]. Fig. (1) summarizes ADMA biosynthesis and metabolism. A wide distribution of two DDAH isoforms in various tissues indicates that the regulation of methylarginines level has critical biological importance [31]. Both intra- and extracellular levels of ADMA may be substantially elevated upon increased protein methylation or proteolysis, decreased DDAH activity, or decreased cationic amino acid transporter (CAT) activity [34]. DDAHs' expression and activity also contribute to the pathogenesis of endothelial dysfunction [10]. DDAH-2 critically determines NO availability in endothelial cells [33], and its gene silencing reduces endothelial-dependent relaxation by 40% [35]. Regulation of plasma ADMA level is highly dependent on factors that affect the expression and activity of DDAH

CHAPTER 5

Nitric Oxide-Related Oral Microbiota Dysbiosis in Type 2 Diabetes

Zahra Bahadoran¹, Pedro González-Muniesa^{2,3,4,5}, Parvin Mirmiran^{1,6} and Asghar Ghasemi^{7,*}

¹ Nutrition and Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

² Department of Nutrition, Food Science and Physiology, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain

³ Center for Nutrition Research; School of Pharmacy and Nutrition, University of Navarra Pamplona, Spain

⁴ CIBER Physiopathology of Obesity and Nutrition (CIBERObn), Carlos III Health Institute (ISCIII), Spain

⁵ IDISNA – Navarra Institute for Health Research, Pamplona, Spain

⁶ Department of Clinical Nutrition and Human Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran

⁷ Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract: The nitrate (NO₃)-nitrite (NO₂)-nitric oxide (NO) pathway, as a storage reservoir for endogenous NO production, is dependent on the oral bacteria with NO₃-reducing capacity. Undesirable changes of oral microbiota towards a decreased load of health-related NO₃-reducing bacteria and an overgrowth of pathogenic species, leading to subsequent decreased NO₂ production in the oral cavity and decreased systemic NO availability, are now considered risk factors for the development of insulin resistance and type 2 diabetes (T2D). This chapter discusses available evidence focusing on oral microbiota dysbiosis in T2D, especially NO₃-reducing bacteria and their metabolic activity (including NO₃-reductase and NO₂-reductase activity), affecting net oral NO₂ accumulation and the NO₃-NO₂-NO pathway.

Keywords: Nitrate, Nitrite, Nitric oxide, Nitrate reductase, Nitrite reductase, Oral microbiota, Type 2 diabetes.

* **Corresponding author Asghar Ghasemi:** Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Ghasemi@endocrine.ac.ir., No. 24, Erabi Street, Velenjak, Tehran, Iran; Phone: +98 21 22409309; Fax: +98 21 22416264.

Asghar Ghasemi, Khosrow Kashfi, Zahra Bahadoran (Eds.)
All rights reserved-© 2022 Bentham Science Publishers

INTRODUCTION

Dysbiosis in the oral microbiota is associated with increased cardiovascular and metabolic disorders [1, 2]. It has been suggested that the link between oral microbiota dysbiosis and cardiometabolic disorders is in part due to decreased abundance of species with nitrate (NO₃)-reducing capacity and concurrent increase of pathogenic bacterial species in the oral cavity [3, 4].

In the oral cavity, the commensal facultative and obligate anaerobic bacteria with NO₃-reducing capacity reduce salivary NO₃ to nitrite (NO₂) *via* a two-electron reduction, using anaerobic respiration by the action of NO₃ reductases (NaRs) [5]. Although mammalian NaRs activity may contribute to mammalian NO₃ reduction and regulation of NO₂ and nitric oxide (NO) metabolism in the human body [6], the role of oral microbiota is of great importance.

Although changes in the composition of oral microbiota in type 2 diabetes (T2D) have been reported [7, 8], this issue remains a matter of debate [9, 10]; T2D is associated with increased loading of diseases-associated oral bacteria and reduced community of health-related bacteria [11]. Since the recycling process of inorganic NO₃ to NO, a ubiquitous endocrine hormone involved in glucose and insulin homeostasis [12], is critically dependent upon oral commensal NO₃-reducing bacteria [13, 14], oral dysbiosis of these communities has been suggested to contribute to the development of insulin resistance T2D [15]. In this chapter, we focus on NO-related oral microbiota dysbiosis in T2D.

AN OVERVIEW OF ORAL MICROBIOTA

The term microbiota describes the ecological community of symbiotic, commensal, and pathogenic microorganisms [16]. Oral microbiota is the second largest, second most diverse, complex, and dynamic microbial community in the human body, including about 775 species of bacteria (12 phyla and 185 genera) [17]. The commensal bacteria resident in the oral cavity interacts with the host in a balanced manner, whereas potentially pathogenic bacteria emerge following an imbalanced oral resident microbiota [18]. The concept of a fluid continuum now replaces the concept of commensalism *vs.* pathogenicity as a fixed duality since labeling bacteria as strict commensals *vs.* pathogens was a too restrictive approach [19].

About 96% of the oral microbiota comprises the six broad phyla, *Firmicutes*, *Actinobacteria*, *Proteobacteria*, *Fusobacteria*, *Bacteroidetes*, and *Spirochaetes* [17, 20]. The *Saccharibacteria*, *Synergistetes*, *SRI*, *Gracilibacteria*, *Chlamydia*, *Chloroflexi*, *Tenericutes*, *Euryarchaeota*, *TM7*, and *Chlorobi* comprise 4% of the remaining taxa [21]. The human oral microbiota database (HOMD) provides a

comprehensive database of oral bacterial taxa, a 16S rRNA identification tool, and genome sequences (www.homd.org).

Although the rat tongue microbiota is less diverse than the human [99 ± 40 vs. 249 ± 30 operational taxonomic units (OUT, a pragmatic proxy for species at different taxonomic levels, and used to categorize bacteria based on sequence similarity); 2.92 ± 0.53 vs. 5.54 ± 0.33 Shannon diversity index], the physiological activity of oral microbiota is comparable in both species [4]. The *Firmicutes* and *Proteobacteria* comprised 40-80% of the tongue communities in both humans and rats; however, the *Actinobacteria* is the predominant phyla in rat tongues, whereas human tongues contained more *Bacteroidetes* [4]. About 70% of human tongue bacterial composition comprises the gram-positive species (mainly *Staphylococcus*, *Micrococcus*, and *Streptococcus*), and 30% are gram-negative [22].

The oral microbiota has both pro- and anti-inflammatory activities that maintain oral homeostasis [23]. The balance between the resident species in the oral cavity determines how the microbiota changes toward a health-related (symbiosis) state or a disease-associated (dysbiosis) state [16]. Factors including poor oral hygiene, gingival inflammation, change in saliva flow rate or composition, aging, medications, diseases, dietary habits, physical activity, smoking, and a poor immune system drive the oral microbiota composition to dysbiosis and overgrowth of pathogenic species [24, 25].

From the metabolic function point of view, oral bacteria contribute to 4 major metabolic pathways: 1) saccharolytic bacteria, including *Streptococcus*, *Actinomyces*, and *Lactobacillus* species that metabolize carbohydrates into organic acids; 2) proteolytic and amino acid-degrading bacteria, including *Fusobacterium*, *Prevotella*, and *Porphyromonas* species that metabolize proteins and peptides into amino acids, and further into short-chain fatty acids, ammonia, sulfur compounds, and indole/skatole) [26]; 3) bacteria like *Streptococcus*, *Actinomyces*, and *Lactobacillus* that contribute to alkalization and acid neutralization via arginine/agmatine deiminase system; 4) species including *Actinomyces* and *Veillonella* with NO_3^- -reducing capacity that convert NO_3^- to NO_2^- and inhibits bacterial acid production [26].

The metabolic activities of oral bacteria are closely related to systemic metabolic health and diseases [16, 26]. Although it is difficult to make a clear distinction, carbohydrate metabolizers and acid-producing bacteria, leading to the accumulation of organic acids, are related to oral dysbiosis. In contrast, those involving accumulating ammonia and NO_2^- and inhibiting acid production are considered health-associated species [16, 26].

CHAPTER 6

Nitric Oxide and Type 2 Diabetes: Lessons from Genetic Studies

Zahra Bahadoran¹, Parvin Mirmiran², Mattias Carlström³ and Asghar Ghasemi^{4,*}

¹ Nutrition and Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

² Department of Clinical Nutrition and Human Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran

³ Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden

⁴ Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract: Nitric oxide (NO), a multifunctional gasotransmitter, is now considered an endocrine hormone that essentially contributes to the regulation of glucose and insulin homeostasis. Here, we discuss current genetic data linking NO metabolism to metabolic disorders, especially insulin resistance and type 2 diabetes (T2D). Although several gene variants of NO synthases [NOSs, *i.e.*, neuronal NOS (nNOS), endothelial NOS (eNOS), and inducible NOS (iNOS)] isoforms have been identified in humans that affect NO bioactivity and metabolism, only the eNOS polymorphisms are reported to be associated with insulin resistance and T2D. Among the functional eNOS gene polymorphisms, the single nucleotide polymorphisms (SNPs) rs2070744 (T786C), rs1799983 (G894T), and rs869109213 (eNOS 4b/4a) are related to the risk of developing insulin resistance and T2D.

Keywords: Endothelial Nitric Oxide Synthase, Gene Polymorphisms, Inducible Nitric Oxide Synthase, Insulin Resistance, Neuronal Nitric Oxide Synthase, Nitric Oxide, Type 2 Diabetes.

INTRODUCTION

Emerging data suggest that impaired nitric oxide (NO) homeostasis is involved in the development of insulin resistance and type 2 diabetes (T2D) [1, 2]. The

* **Corresponding author Asghar Ghasemi:** Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran; No. 24, Erabi Street, Velenjak, Tehran, Iran; Phone: +98 21 22409309; Fax: +98 21 22416264, Email: Ghasemi@endocrine.ac.ir

critical role of NO on glucose and insulin homeostasis is greatly supported by findings of the genetically-modified animal models, including NO synthase (NOS) gene knockout models or over-expressed NOSs [3 - 5]. Extrapolation of the results obtained in the genetically-modified NOS isoforms in the animal models to humans is not straightforward; however, studies that investigated gene polymorphisms of human NOSs confirm the relation between NO metabolism and the development of insulin resistance and T2D.

Among several reports on NOS gene polymorphisms, endothelial NOS (eNOS) gene variants have gained enormous attention due to their association with hypertension and cardiovascular diseases; a meta-analysis of 155 published studies showed that the most common eNOS polymorphisms, *i.e.*, rs1799983 (G894T), rs2070744 (T786C), and rs869109213 (eNOS 4b/4a) are significantly associated with coronary artery disease in the general populations [6]. Another meta-analysis of 74 studies showed that the eNOS polymorphisms G894T and T786C increase the risk of hypertension by about 16-40% among different populations [7].

The genetic variants of eNOS that have formerly been reported for individual susceptibility to vascular dysfunction and hypertension [8] are now considered the risk factors for insulin resistance and T2D [9 - 12]. These functional eNOS polymorphisms affect gene expression or protein structure of eNOS, resulting in inadequate eNOS-derived NO production and impaired glucose and insulin homeostasis [9]. Here, we review genetic evidence linking NO metabolism to metabolic disorders, especially insulin resistance and T2D.

A BRIEF OVERVIEW OF NOS ENZYMES: GENE STRUCTURE AND CHROMOSOMAL LOCALIZATION

The enzymatic NO synthesis pathway is mediated by NO synthase (NOS), in which *L*-arginine is converted to NO by constitutive or inducible isoforms of NOSs, including eNOS (EC 1.14.13.39), neuronal NOS (nNOS, EC 1.14.13.39), and inducible NOS (iNOS, EC 1.14.13.39) [13, 14].

The NOSs are flavoheme homodimer enzymes (with two functional domains in each monomer: oxygenase and reductase domains), which catalyze the formation of NO through two consecutive monooxygenation reactions [14, 15]; calmodulin (CaM)-binding region in the middle of the molecule, has been called the third NOSs domain in some papers [16]. Both nNOS and eNOS are activated by the reversible binding of CaM at elevated intracellular Ca²⁺ levels; CaM binds to the linker region between the reductase and oxygenase domains and activates the enzyme by inducing intramolecular electron transfer [17]. The main characteristics of NOS isoforms are summarized in Table 1. In addition, a number

of splice variants (nNOS μ , nNOS β , and nNOS δ) are translated from the nNOS gene [18].

The human eNOS gene is located in the 7q36.1 region of chromosome 7 and comprises 28 exons (<https://www.ncbi.nlm.nih.gov/gene/4846>). The human eNOS gene has a length of 21-22 kb and encodes an mRNA of 4052 nucleotides [19]. The eNOS promoter region is TATA-less, includes Sp1 and GATA motifs, and has several binding sites for transcription factors, *i.e.*, activator proteins (AP-1 and AP-2), nuclear factors [nuclear factor-1 (NF-1), interleukin-6 (IL-6), nuclear factor κ B (NF- κ B)], Ets protein polyomavirus enhancer activator 3 (PEA3), 1 myc-associated zinc-finger protein (MAZ), 1 Ying Yang (YY1), acute-phase response elements, shear-stress response elements, and sterol regulatory elements [20 - 22].

The eNOS promoter sequence also contains several half-sites of the estrogen- and glucocorticoid-responsive elements [21]. Mutation of the Sp1 site decreased human eNOS promoter activity by about 85%, whereas deletion of the GATA binding site completely inactivated the eNOS promoter [23].

Table 1. Characteristics of NOS isoforms.

	NOS Isoforms		
	Constitutive		Inducible
	nNOS (NOS1)	eNOS (NOS3)	iNOS (NOS2)
Main sites of expression [24]	Brain	Endothelial cells	Macrophages in the liver, kidney, and lung
Other sites of expression [24 - 26]	Spinal cord, sympathetic ganglia, and adrenal glands, peripheral nitrenergic nerves, epithelial cells, pancreatic islet cells, cardiac and skeletal myocytes, smooth muscle cells, renal macula densa cells	Red blood cells, alveolar macrophages, placenta, kidney tubular epithelial cells	Cytokine-induced cells
Physiological functions [27]	Learning and memory processes, regulation of systemic blood pressure, renal autoregulation, and local cerebral blood flow	Regulation of vascular tone	Implicated in immune defense, antitumor and antimicrobial activities
Cellular localization [27]	Cytoplasm, mitochondria, and plasma membrane	Plasma membrane caveolae and cytoplasm	Cytoplasm
Human locus (Gene ID) [25]	4842	4846	4843

Role of Nitric Oxide in Diabetic Wound Healing

Hamideh Afzali¹, Tara Ranjbar², Khosrow Kashfi² and Asghar Ghasemi^{1,*}

¹ Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

² Department of Molecular, Cellular, and Biomedical Sciences, Sophie Davis School of Biomedical Education, City University of New York School of Medicine, New York, NY 10031, USA

Abstract: Nitric oxide (NO), a gaseous free radical, is a key signaling molecule in the different phases of the normal wound healing process. The beneficial effects of NO in wound healing are related to its antibacterial properties, regulation of inflammatory response, stimulation of proliferation and differentiation of keratinocytes and fibroblasts, and promotion of angiogenesis and collagen deposition. NO deficiency is an important mechanism responsible for poor healing in diabetic wounds. In this chapter, the function of NO in diabetic wound healing and the possible therapeutic significance of NO in the treatment of diabetic wounds are discussed. Current knowledge supports this notion that NO-based intervention is a promising therapeutic approach for diabetic wound healing.

Keywords: Advanced glycated end products, Coagulation, Diabetic foot ulcer, Endothelial nitric oxide synthase, Hexosamine pathway, Hyperglycemia, Neuropathy, Nitric oxide, Peripheral arterial disease, Polyol pathway, Protein kinase C, Reactive oxygen species, Superoxide anion, Wound healing.

INTRODUCTION

The worldwide prevalence of diabetes is increasing [1]. Delay in wound healing is one of the most disabling problems in diabetes [2]. Results of a systematic review and meta-analysis indicate that the global prevalence of diabetic foot ulcer (DFU) is 6.3%, and this prevalence is higher in men (4.5%) than in women (3.5%) and type 2 (6.4%) than in type 1 (5.5%) diabetic patients [3]. The lifetime risk for developing DFU in a diabetic patient is ~25% [4]. Compared to diabetic patients without ulcers, those with DFU have a 50% higher risk of mortality [5] and a 10-20 times more chance of lower limb amputation [6]. In addition, the yearly cost of

* **Corresponding author Asghar Ghasemi:** Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Ghasemi@endocrine.ac.ir., No. 24, Erabi Street, Velenjak, Tehran, Iran; Phone: +98 21 22409309; Fax: +98 21 22416264.

care for people with diabetes and foot ulcers is 5.4 times higher than for people with diabetes but without foot ulcers [7]. Diabetic patients with DFU have a lower quality of life [8] since chronic wounds decrease a patient's ability to do simple tasks and social functions and are among the leading causes of hospitalization [2, 8]. Current standard care for a diabetic wound is debridement, pressure offloading, appropriate dressing, and infection and glycemic control [9, 10]. However, the current treatment for DFU seems insufficient since a meta-analysis of randomized clinical trials reported that healing rates are 24.2% and 30.9% at 12 and 20 weeks among patients with neuropathic DFU who received standard care [11]. In addition, a recent meta-analysis demonstrated that the global recurrence rate of DFU was high, with 22.1% per person-year [12]. The increasing prevalence of diabetes, adverse effects of DFU on a patient's quality of life, and the high economic burden of DFU warrant further research for finding new therapeutic strategies for more effective wound management in diabetic patients. Understanding pathophysiological mechanisms that interrupt the normal wound healing process in diabetic patients helps in finding new treatments.

Nitric oxide (NO) plays a significant role in skin pathophysiological responses, such as vasodilation, response to ultraviolet (UV) irradiation, inflammation, and apoptosis, and therefore affects several distinct aspects of wound healing [13]. NO regulates inflammatory response during the wound healing process, stimulates proliferation and differentiation of keratinocytes and fibroblasts, promotes angiogenesis and collagen deposition, and has antibacterial properties [14 - 16].

Decreased NO bioavailability in diabetes is an important factor in poor ulcer healing [17], and, therefore, NO-based therapies for DFU have received increasing attention in recent years. NO's role as a mediator in normal wound healing has been reviewed extensively [14 - 16]. This chapter summarizes NO's role in diabetic wound healing and discusses the potential applications of NO-based treatment strategies in diabetic wounds.

Types of Wound

A wound is created following disruption of skin integrity, mucosal surfaces, or organ tissues [18]. According to the healing time, wounds are classified as acute and chronic types [19]. Acute wounds (*e.g.*, surgical incisions) heal quickly through an orderly and timely process [18] in 5-10 days [19] or within 30 days from injury [19, 20]. Chronic wounds (*e.g.*, diabetic ulcers, pressure ulcers, and venous ulcers) are not repaired after 12 weeks of initial insult [18, 20]. These wounds cannot produce anatomical and functional integration of the injury site through an orderly and timely process [21].

Chronic wounds, which make up to ~70% of all skin wounds, are characterized by prolonged pathological inflammation, persistent infections, the inability of epidermal and/or dermal cells to respond to repair stimuli, and the formation of drug-resistant microbial biofilms [22]. Chronic ulcers are rarely seen in healthy people [21] and are more common in people with diabetes, obesity, or spinal cord injury [21].

Pathophysiology of Diabetic Foot Ulcer

Peripheral neuropathy and peripheral arterial disease (PAD) are the two main risk factors that lead to DFU [23]. More than 60% of DFUs result from underlying peripheral neuropathy [23]. PAD incidence is 2–4 times more common in patients with diabetes compared to non-diabetic individuals [24].

Peripheral Neuropathy

Increased levels of intracellular advanced glycated end products, increased hexosamine pathway flux and polyol pathway, activation of protein kinase C (PKC), and reduction of endothelial nitric oxide synthase (eNOS) expression are the main mechanisms causing hyperglycemic nerve damage [23, 25]. Neuropathy in diabetic patients is reflected in sensory, motor, and autonomic nervous system divisions [23].

Sensory neuropathy is the most common predictor of DFU in diabetes [4] and causes damage to sensation, which protects against stimuli, such as heat, pressure, and pain [4]. As a result, these patients are less sensitive to pressure-related trauma or other minor skin injuries, increasing their susceptibility to injury [4]. Damage to the motor nerves in the motor neuropathy causes deformities in the foot, abnormal foot pressure, and subsequent callus formation. It will gradually cause skin damage and create a wound [23]. In autonomic neuropathy, the foot becomes dry due to decreased secretory functions of the sebaceous and sweat glands [4]. Dry skin is prone to fissures and thus creates a site vulnerable to microbial infection [4].

Peripheral Arterial Disease (PAD)

PAD is characterized by stenosis or occlusion of the lower limb's arteries [26]. It commonly affects the tibial and peroneal arteries of the calf. It leads to acute or chronic ischemia, and in combination with digital artery disease, it also impairs wound healing by affecting circulation and blood flow of the lower limbs [23].

Hyperglycemia, smoking, age, hypertension, and hyperlipidemia are the most important risk factors for PAD [26]. Endothelial dysfunction decreases NO

CHAPTER 8

Role of Nitric Oxide in Type 2 Diabetes-Induced Osteoporosis

Nasibeh Yousefzadeh¹, Sajad Jeddi¹, Khosrow Kashfi² and Asghar Ghasemi^{1,*}

¹ Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

² Department of Molecular, Cellular and Biomedical Sciences, Sophie Davis School of Biomedical Education, City University of New York School of Medicine, New York, NY 10031, USA

Abstract: Osteoporosis affects 200 million people worldwide. Osteoporosis in subjects with diabetes is called diabetoporosis, and type 2 diabetes (T2D) contributes to and aggravates osteoporotic fractures. Hyperglycemia, insulin resistance, bone vasculature impairment, increased inflammation, oxidative stress, and bone marrow adiposity contribute to a higher incidence of osteoporotic fractures in T2D. Decreased nitric oxide (NO) bioavailability due to lower endothelial NO synthase (eNOS)-derived NO and higher inducible NOS (iNOS)-derived NO is one of the main mechanisms of the diabetoporosis. Available data indicates that T2D increases osteoclast-mediated bone resorption and decreases osteoblast-mediated bone formation, mediated in part by reducing eNOS-derived NO and increasing iNOS-derived NO. NO donors delay osteoporosis and decrease osteoporotic fractures in subjects with T2D, suggesting the potential therapeutic implication of NO-based interventions for diabetoporosis.

Keywords: Bone mineral density, Bone marrow stromal cells, Diabetoporosis, Endothelial nitric oxide synthase, Inducible nitric oxide synthase, Nitric oxide, Osteoporosis, Type 2 diabetes.

INTRODUCTION

Osteoporosis is a silent illness that affects 200 million people worldwide [1 - 3] and is generally diagnosed after an osteoporotic fracture [4, 5]. Osteoporosis is characterized by low bone mineral density (BMD) and deterioration of the bone microarchitecture [6, 7]. Osteoporosis causes about 9 million fractures annually, severely impacting patients' quality of life and imposing high healthcare costs [1, 8]. In addition, ~40% of older women will experience an osteoporotic fracture during their lifetime [5, 9], increasing their mortality rate by 15-20% [10 - 13].

* **Corresponding author Asghar Ghasemi:** Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Ghasemi@endocrine.ac.ir., No. 24, Erabi Street, Velenjak, Tehran, Iran; Phone: +98 21 22409309; Fax: +98 21 22416264.

Osteoporosis is generally associated with senescence and estrogen deficiency; however, other factors, including diabetes, contribute to and deteriorate osteoporotic fracture [14]. Osteoporosis in subjects with diabetes was firstly reported by Albright and Reifense in 1948 and named diabetoporosis by Ferrari S. in 2015 [15].

Diabetoporosis is one of the leading causes of osteoporotic fractures [14] and is characterized by decreased bone quality and quantity [16]. According to population-based studies conducted from 1980 to 2016, the risk of osteoporotic fractures has been increased in subjects with both type 1 diabetes (T1D) and type 2 diabetes (T2D) [17 - 21]. The risk of osteoporotic fractures is 200-700% higher in subjects with T1D [17, 22, 23] and 40-80% higher in subjects with T2D [22, 24]. In addition, fracture healing is delayed in subjects with T1D and T2D; a study of 5966 cases of hip fracture in patients with T1D and T2D showed that these patients required longer in-hospital stay [25]. These data emphasize the need for developing new strategies against osteoporotic fractures in patients with diabetes, especially in subjects with T2D, which accounts for ~90% of diabetic subjects [26].

Nitric oxide (NO) bioavailability is decreased in the bones of humans and animals with T2D and can be considered one of the primary mechanisms underlying diabetoporosis [27]. NO is produced in bone cells by the three isoforms of NO synthase (NOS) enzymes, including endothelial, neural, and inducible NOS (eNOS, nNOS, and iNOS, respectively) [28, 29].

NO in the bone acts as a double-edged sword; a low level of NO increases osteoblast-mediated bone formation [30, 31], decreases osteoclast-mediated bone resorption [32, 33], has protective effects against osteoporotic fractures, and increases the rate of bone healing [30, 34] in postmenopausal women and ovariectomized rats. A high NO level has adverse effects on bone cells' activity [28, 35]. eNOS^{-/-} rodents have decreased osteoblast [36] and increased osteoclast activities [37 - 39] that are associated with lower trabecular bone volume and cortical thickness as well as lower BMD [40, 41]. These changes increase the risk of osteoporotic fractures [42] and decrease the rate of the bone healing process [43] in eNOS^{-/-} rodents. In addition, iNOS^{-/-} rodents show reduced bone growth and bone length [44] only in pre-natal but not in adult bones [44]. Reduced osteoclasts and osteoblasts in nNOS^{-/-} rodents are associated with lower bone remodeling [45, 46]. nNOS^{-/-} rodents have lower bone remodeling and lower numbers of osteoclasts and osteoblasts. The effect of NO on bone function in healthy subjects has been previously reviewed [47, 48]. This chapter deals with the role of NO in diabetoporosis.

NITRIC OXIDE AND BONE: A BRIEF OVERVIEW

The effect of NO on bone function is dependent on its concentration; a low level of NO is beneficial for several physiological functions of bone, including normal bone formation [49, 50], development [28, 51], remodeling [52], and fracture healing [53], whereas, a high NO level has detrimental effects on all of these functions [28]. In support of this notion, low and middle doses of nitroglycerin, as a NO donor, stimulate osteoblast activity and bone formation [35], but its high doses decrease osteoblast activity [35] and thus decrease the rate of bone turnover [35].

Regarding the effects of NO on osteoclast activity and bone resorption, it has been reported that a low level of NO may be necessary for normal osteoclast activity; this proposition rests on observations that NOS inhibitors inhibit the activity and motility of isolated osteoclasts [34, 54]. However, a high NO level inhibits osteoclast formation and activity and promotes apoptosis in osteoclasts [35].

There is a substantial body of evidence showing that the cyclic guanosine monophosphate (cGMP)-dependent signaling is vital for normal bone formation [50], and cGMP has been proposed as the primary mediator of NO on bone function [52]. The stimulatory effects of NO on osteoblasts are mediated by cGMP since it is abolished by guanylate cyclase (GC) inhibitors [55]. NO, *via* activation of soluble GC (sGC), increases osteoblastic bone formation [56], whereas the effect of NO on osteoclasts is mainly inhibitory and, in part, cGMP-independent [47, 56]. NO *via* activation of sGC is also a key regulator of angiogenesis in the bone that plays an essential role in bone repair [57]. In addition, NO, *via* core-binding factor alpha 1 (a critical transcription factor for osteoblastic differentiation and osteogenesis)/cGMP/PKG pathway, increases matrix metalloproteinase-13 (MMP-13) expression in osteoblasts, which is an essential factor for bone development [28, 51]; therapeutic effects of estrogen in bone are also in part mediated by the eNOS/cGMP pathway [55, 58, 59].

NOS Expression in the Bone Cells

NO is produced in the bone cells by eNOS, nNOS, and iNOS [55, 60 - 62]. eNOS is mainly expressed in osteoblasts and osteocytes [63, 64], but its expression has also been documented in osteoclasts and bone marrow stromal cells [55, 65]. eNOS is also expressed in chondrocytes of the epiphyseal growth plate, mainly in the first four weeks of the neonatal period, and after that, it declines with age [66]. iNOS is expressed in osteoclasts in neonatal rats under physiological conditions [66]; in adults, it is expressed in response to pro-inflammatory cytokines under pathological conditions in all bone cells [54, 67, 68].

Hyperuricemia, Type 2 Diabetes and Insulin Resistance: Role of Nitric Oxide

Zahra Bahadoran¹, Parvin Mirmiran^{1,2}, Khosrow Kashfi^{3,4} and Asghar Ghasemi^{5,*}

¹ Nutrition and Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

² Department of Clinical Nutrition and Human Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran

³ Department of Molecular, Cellular, and Biomedical Sciences, Sophie Davis School of Biomedical Education, City University of New York School of Medicine, New York, NY10031, USA

⁴ Graduate Program in Biology, City University of New York Graduate Center, New York NY10016, USA

⁵ Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract: Uric acid (UA) is the end product of purine catabolism in humans. Hyperuricemia, defined as elevated plasma concentrations of UA above 7 mg/dL, is a risk factor for developing hypertension, cardiovascular diseases, chronic kidney disease, and type 2 diabetes. Hyperuricemia can induce pancreatic β -cell death and impaired insulin secretion. It can also disrupt insulin-induced glucose disposal and insulin signaling in different insulin-sensitive tissues, including cardiomyocytes, skeletal muscle cells, adipocytes, hepatocytes, and endothelial cells. These events lead to the development of systemic insulin resistance and impaired glucose metabolism. Induction of inflammation, oxidative stress, and impairment of nitric oxide (NO) metabolism mediate hyperuricemia-induced insulin resistance and dysglycemia. This chapter is focused on the potential mediatory role of NO metabolism on hyperuricemia-induced dysglycemia and insulin resistance.

Keywords: Hyperuricemia, Insulin Receptor, Insulin Resistance, Type 2 Diabetes, Uric Acid.

* **Corresponding author Asghar Ghasemi:** Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran; No. 24, Erabi Street, Velenjak, Tehran, Iran; Phone: +98 21 22409309; Fax: +98 21 22416264, Email: Ghasemi@endocrine.ac.ir

INTRODUCTION

Uric acid (UA), the end product of adenine- and guanine-based purines catabolism in humans, is synthesized by xanthine oxidoreductase (XOR) from xanthine [1]. Both endogenous (*i.e.*, de novo purine biosynthesis as well as cell and tissue turnover) and exogenous (*i.e.*, dietary purines occurring in the seafood, meats, and legumes) sources of purines are involved in UA production [2 - 4]. Increased plasma concentrations of UA above 7 mg/dL (1 mg/dL \approx 59.48 μ M), which accompanies by a doubled amount of exchangeable pool of UA (from 1200 to 2027 mg) and also hyperuricosuria (urinary excretion of UA > 800 mg/day in men and >750 mg/day in women) [4, 5], is the primary cause of gout [6].

Hyperuricemia is a risk factor for developing cardiometabolic disorders, including hypertension [7, 8], cardiovascular diseases [9, 10], chronic kidney disease [11], type 2 diabetes (T2D) [12 - 15], and mortality [16, 17]. In addition, hyperuricemia has been suggested as a component of metabolic syndrome, the cluster of metabolic and hemodynamic abnormalities, including abdominal obesity, glucose intolerance, insulin resistance, dyslipidemia, and hypertension [18]. Although not fully established, current documents imply that increased plasma UA concentration is a causative factor for developing insulin resistance and dysglycemia [12, 13].

Several mechanisms may explain the cause-and-effect relationship between hyperuricemia and the progression of T2D; high-UA concentrations can induce pancreatic β -cell death and impaired insulin secretion [19, 20]. High-UA can also disrupt insulin-induced glucose disposal and insulin signaling in various insulin-sensitive tissues, including cardiomyocytes [21], skeletal muscle cells [22], adipocytes [23], hepatocytes [24], and endothelial cells [25]; these events consequently lead to the development of systemic insulin resistance [26, 27]. Induction of oxidative stress, inflammatory processes, and impaired nitric oxide (NO) metabolism are crucial underlying mechanisms by which high-UA concentration imposes detrimental effects on glucose and insulin homeostasis.

In this chapter, considering both epidemiological and experimental evidence, we discuss the potential cause-and-effect relation between hyperuricemia and T2D and insulin resistance development. Furthermore, we focus on the possible mediating role of NO in hyperuricemia-induced dysglycemia and insulin resistance.

A BRIEF OVERVIEW OF URIC ACID METABOLISM AND FUNCTION

Uric Acid Synthesis In Human: Role of XOR

Uric acid is a weak hydrogenated organic acid (pK_{a1} of 5.75 and pK_{a2} of 10.3); under normal conditions, *i.e.*, pH 7.4 and 37°C, the most predominant (~98-99%) form of UA within the circulation and synovial fluid is urate anion (*i.e.*, mono-deprotonated ionic form) [28]. Uric acid synthesis mainly occurs in the liver, whereas other tissues, such as the intestine, myocardium, kidney, and vascular endothelium, also contribute to UA synthesis to a lesser extent [29]. UA is the metabolic end product of purine in humans (due to lack of uricase); it can be, however, be diverted into further catabolism by uricase to produce allantoin in other mammals [2, 30]; loss of uricase activity in humans has been an evolutionary process, which allowed them to readily accumulate fat *via* the metabolism of fructose from fruits [31].

Many enzymes, including nucleotidase, adenosine deaminase, and purine nucleoside phosphorylase, participate in the purine catabolism [*i.e.*, converting adenosine monophosphate (AMP), and guanine monophosphate (GMP) to inosine and guanosine, respectively, and then into hypoxanthine (HPX)]. XOR, which converts HPX into xanthine and then to UA, is the key and rate-limiting enzyme in the pathway [1].

Positive regulators of XOR gene expression are hypoxia, lipopolysaccharide, inflammatory cytokines [interferon γ , interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor- α (TNF- α)], dexamethasone, cortisol, and prolactin [32]. In addition to oxygen pressure, NO can also modify XOR activity; exogenous NO and also NO produced by XOR (reduction of nitrite to NO *via* xanthine as reducing substrate) are accompanied by the enzyme inactivation (through NO-induced conversion of xanthine to its desulfo-form) and inactivates XOR [33, 34].

The maximum XOR activity in mammals is in the liver and intestinal epithelial cells; XOR is mainly located in the cytoplasm and cell membrane through cell surface binding mediated by glycosaminoglycans [35, 36]. As reviewed elsewhere, besides purines, XOR can also catabolize different endogenous metabolites (*i.e.*, aldehydes, pyrimidines, pteridines, azopurines, and heterocyclic compounds) and different xenobiotics (*e.g.*, antiviral and anticancer agents) [37, 38].

Regulation of Circulating Uric Acid Levels

Normal serum UA concentration is 3.5-7.2 mg/dL in adult men and postmenopausal women and 2.6-6.0 mg/dL in premenopausal women; however, a

Therapeutic Management of Type 2 Diabetes: The Nitric Oxide Axis

Tara Ranjbar¹, Jennifer L. O'Connor^{1,2} and Khosrow Kashfi^{1,3,*}

¹ *Department of Molecular, Cellular, and Biomedical Sciences, Sophie Davis School of Biomedical Education, City University of New York School of Medicine, New York, NY, USA*

² *Department of Chemistry and Physics, State University of New York at Old Westbury, Old Westbury, NY, USA*

³ *Graduate Program in Biology, City University of New York Graduate Center, New York, NY, USA*

Abstract: According to the World Health Organization (WHO), the prevalence of obesity across the globe has nearly tripled since 1975, with 39 million children under the age of 5 being overweight or obese in 2020. Obesity is the most common risk factor for developing type 2 diabetes (T2D), which may lead to elevated serum triglycerides, hypertension, and insulin resistance. In the pathogenesis of T2D, there is a reduction in nitric oxide (NO) bioavailability. Restoration of NO levels has been associated with many favorable metabolic effects in T2D. Drugs that potentiate NO levels may have a role in improving T2D-associated adverse effects. Current medications approved for use in the management of T2D include biguanides, thiazolidinediones, sulfonylureas, meglitinides, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, alpha-glucosidase inhibitors, and sodium-glucose co-transporter 2 (SGLT2) inhibitors. These drugs mitigate the many adverse effects associated with T2D. This chapter discusses these classes of drugs, examines their mechanism of action, and presents evidence that these drugs directly or indirectly modulate NO levels.

Keywords: Alpha-glucosidase inhibitors, Biguanides, Dipeptidyl peptidase-4 inhibitors, Glucagon-like peptide-1, Glucagon-like peptide-1 receptor agonists, Meglitinides, Metformin, Nitric oxide, Sodium-glucose co-transporter, Sodium-glucose co-transporter inhibitors, Sulfonylureas, Thiazolidinediones, Type 2 diabetes.

* **Corresponding author Khosrow Kashfi:** Department of Molecular, Cellular, and Biomedical Sciences, Sophie Davis School of Biomedical Education, City University of New York School of Medicine, New York, NY, USA, Graduate Program in Biology, City University of New York Graduate Center, New York, NY, USA; kashfi@med.cuny.edu.

INTRODUCTION

In 1825, Jean Anthelme Brillat-Savarin wrote, in *Physiologie du Gout, ou Meditations de Gastronomie Transcendante*: “Dis-moi ce que tu manges, je te dirai ce que tu es.” (Tell me what you eat and I will tell you what you are) [1]. The German philosopher and anthropologist Ludwig Andreas von Feuerbach, in an essay titled *Concerning Spiritualism and Materialism*, wrote: “Der Mensch ist, was er ißt” (man is what he eats) [2, 3]. The food you eat is a reflecting image of yourself. Thus, maintaining a well-balanced and healthy diet is essential for good health.

According to the World Health Organization (WHO), the prevalence of obesity across the globe has nearly tripled since 1975, with 39 million children under the age of 5 being overweight or obese in 2020 [4]. In the United States, approximately one-third of the adult population is obese, and an additional one-third is overweight [5]. Obesity is the fastest-growing lethal disease in Western and developing countries. People do not die from obesity itself but from its complications, which shorten their lifespan [6, 7]. Type 2 diabetes (T2D), referred to as adult-onset or non-insulin-dependent diabetes, accounts for over 90-95% of all diabetes. It is a complex chronic metabolic disorder characterized by alterations in lipid metabolism, insulin resistance, hyperglycemia, and pancreatic β -cell dysfunction [8]. Since in T2D, patients are unable to store and utilize their glucose within the muscles, adipose tissues, and liver [9], these patients are in a constant hyperglycemic state [10]. Risk factors associated with the development of T2D include obesity, especially in the intra-abdominal region, sedentary lifestyle, and family history [11]. For this reason, T2D patients are often overweight, but weight loss and exercise can improve their blood glucose levels.

Many complications are associated with T2D, including cardiovascular disease, kidney disease, peripheral neuropathy, and cataracts [12]. One mechanism by which high glucose levels can affect the heart is its non-enzymatic glycation and cross-link, which produces “advanced glycosylation end products” (AGEs) [13]. The AGEs trap circulating low-density lipoprotein cholesterol (LDL-C) within the medium and large-sized vessels leading to atherosclerosis [14]. Depending on the location of this atherosclerosis, it can lead to coronary artery disease, stroke, and peripheral vascular disease. When the AGEs are within the smaller sizes arteries and arterioles, this may cause diabetic kidney disease and renal failure [15]. For these reasons, type 2 diabetic patients need to maintain appropriate blood glucose levels to reduce the risks of these complications.

In the pathogenesis of T2D, there is a reduction in nitric oxide (NO) bioavailability [16]. Restoration of NO levels has been associated with many

favorable metabolic effects in T2D [16]. NO is produced in all tissues by NO synthase (NOS)-dependent and independent pathways [16]. There are three isoforms of NOS, neuronal (nNOS/NOS-1), inducible (iNOS/NOS-2), and endothelial (eNOS/NOS-3), with all three being expressed in the pancreatic β -cells [16]. Drugs that potentiate NO levels may have a role in improving T2D-associated adverse effects. Current drugs approved for use in the management of T2D include biguanides, thiazolidinediones, sulfonylureas, meglitinides, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, alpha-glucosidase inhibitors, and sodium-glucose co-transporter 2 (SGLT2) inhibitors [17, 18]. These drugs mitigate the many adverse effects associated with T2D. This chapter discusses these classes of drugs, examines their mechanism of action, and presents evidence that these drugs directly or indirectly modulate NO metabolism.

BIGUANIDES

General Mechanism of Action

Although the term biguanides refer to a whole class of oral T2D drugs, metformin (N, N-Dimethylbiguanide) [widely known as glucophage] is the only approved biguanide derivative currently available for the treatment of hyperglycemia. It is on the World Health Organization's List of Essential Medicines [19]. Metformin is a first-line T2D drug used to reduce blood glucose levels [20] and body weight [21]. Generally, it is prescribed as monotherapy for treating T2D, but it can also be used in combination with other medications, such as pioglitazone and vildagliptin, which are thiazolidinediones and DPP-4 inhibitors, respectively [22]. The functional purpose of metformin is to lower both the basal and postprandial plasma glucose levels [23]. It decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity by increasing peripheral glucose uptake/utilization by the skeletal muscles and adipocytes [22, 23]. Metformin has also been shown to be an effective drug to reduce weight in insulin-sensitive and insulin-resistant overweight and obese patients [24].

The hepatocytes take up metformin through the organic cation transporter-1 (OCT-1) [25]. Its mechanism of action involves reducing hepatic glucose production by inhibiting gluconeogenesis while maintaining insulin uptake by the periphery [26]. At the molecular level, metformin has been found to inhibit the hepatic mitochondrial respiratory chain at complex I [27], which ultimately leads to the activation of AMP-activated protein kinase (AMPK) [28]. AMPK is a heterotrimeric enzyme involved in metabolic regulation [29] and is composed of a catalytic subunit and two regulatory subunits [30]. The catalytic subunit of this

Brain Insulin Resistance, Nitric Oxide and Alzheimer's Disease Pathology

Zhe Pei¹, Kuo-Chieh Lee¹, Amber Khan^{1,2} and Hoau-Yan Wang^{1,2,*}

¹ Department of Molecular, Cellular and Biomedical Sciences, City University of New York School of Medicine, 160 Convent Avenue, New York, New York 10031, USA.

² Department of Biology, Neuroscience Program, Graduate School of The City University of New York, 365 Fifth Avenue, New York, New York 10061, USA.

Abstract: Alzheimer's disease (AD) is a devastating age-related neurodegenerative disease characterized by progressive pathological changes and functional and cognitive impairments. Brain insulin resistance appears to contribute significantly to the pathology and cognitive deficits among several pathological mechanisms. Brain insulin resistance has been demonstrated in animal models of AD and postmortem human brain tissue from patients with AD dementia. Studies conducted in AD models and humans suggest attenuating brain insulin resistance by agents such as glucagon-like peptide1 (GLP-1) analogs and small molecule drug candidate PTI-125 reduces many AD pathologic features and symptoms. Insulin affects NO levels by activating endothelial and neuronal nitric oxide synthase (eNOS, nNOS), and systemic insulin resistance has been linked to reduced nitric oxide (NO) bioavailability. Increasing NO availability reduces systemic insulin resistance, and the insulin signaling pathway is associated with the activation of eNOS, implying a causal relationship. This chapter explores this relationship and the role of impaired NO availability in brain insulin resistance in AD dementia.

Keywords: α -Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid (AMPA) Receptor, CaMKII (Calcium-Calmodulin-Dependent Kinase II), Gamma-Aminobutyric acid (GABA) Receptor, Glutamate, Insulin Resistance, NADPH Oxidase 2 (Nox2), NADPH Oxidase Subunit NOX2, NG-Monomethyl-L-Arginine (L-NMMA), Nitric Oxide Synthase (NOS), N-methyl-D-Aspartate (NMDA) Receptor, Reactive Oxygen Species (ROS), Type-2 Diabetes (T2D).

* **Corresponding author Hoau-Yan Wang:** Department of Molecular, Cellular and Biomedical Sciences, City University of New York School of Medicine, 160 Convent Avenue, New York, NY 10031, USA. Email: hywang@med.cuny.edu

INTRODUCTION

Alzheimer's disease (AD) is a progressive neurodegenerative disorder with many underlying pathophysiological changes that gradually lead to dementia [1 - 4]. The lack of effective treatments for AD dementia and the enormous socioeconomic impact on society underscores the urgent need to develop effective treatments for this devastating disease [5, 6]. Many promising therapeutic agents in development for AD aim to reduce brain insulin resistance, a common early pathological feature of AD dementia with or without diabetes [7 - 10]. The pathological factors that contribute to brain insulin resistance are not fully understood. Nitric oxide (NO) is one of several biological molecules that interact with the insulin signaling pathway bi-directionally. In this chapter, we discuss the role of the NO system in the development of brain insulin resistance and explore the possibility that manipulating NO might be therapeutic for AD dementia.

INSULIN RECEPTOR SIGNALING AND ITS INTERACTION WITH NO SYSTEM

Insulin, a peptide secreted by the beta (β) cells in the pancreas, crosses the blood-brain barrier in a regulated and saturable manner to enter the central nervous system (CNS). Although de novo synthesis of insulin in the brain is still debated, support for local brain insulin synthesis includes the detection of C-peptide and insulin mRNA in various brain regions in humans, with the mRNA levels, being especially high in the hippocampus, striatum, and thalamus [11 - 15]. Insulin expression is decreased in AD compared to normal controls [14].

Insulin produces its cellular actions by binding its cognate insulin receptors (IRs) present on all cells, including neurons and glia in brain regions such as the olfactory bulb, cerebral cortex, hippocampus, hypothalamus, and amygdala [8, 16, 17]. IRs are more concentrated in neurons relative to glial cells and are particularly highly expressed in postsynaptic densities [8, 16 - 18]. Upon insulin binding to the extracellular α -subunit domains of IRs, the intracellular IR β -subunit domains dimerize, leading to activation of their intrinsic tyrosine kinase to cause autophosphorylation. Insulin-like growth factor-1 (IGF-1) also binds and activates IRs with lower affinity, leading to the same trophic and metabolic actions as insulin, including neuronal plasticity [19, 20].

In addition to regulation of glucose utilization and homeostasis, insulin activates PI3K-Akt (Phosphoinositide 3-kinase - Protein kinase B/Akt) and mTOR (Mechanistic target of rapamycin) signaling *via* recruitment of insulin receptor substrate family (IRS) proteins, such as IRS-1 and IRS-2. This insulin-stimulated PI3K/Akt/mTOR pathway has many other functions in cells throughout the body, including the neuronal and vascular systems. Insulin activates Akt *via* IRS1-PI3K

to directly phosphorylate serine1177 residues and activate vascular endothelial NO synthase (eNOS), leading to NO production and consequent vasodilation and increased capillary blood flow [21, 22]. Insulin signaling promoting NO-mediated vasodilation in the brain is supported by increased blood flow in the insular cortex following intranasal insulin in men, independent of cortisol manipulation [23]. Expression of eNOS has been shown not only in the endothelium of the cerebrovasculature but, more importantly, in dendritic spines [24].

Innate eNOS activity confers protection against secondary neuronal injury; thus, impaired eNOS due to insufficient insulin signaling in the brain can conceivably contribute to pathologies in AD, leading to cognitive impairments [25].

Insulin has been shown to modulate a wide range of neuronal functions. Insulin regulates 1) trafficking of ligand-gated ion channels, 2) expression and localization of GABA (γ -Aminobutyric acid), NMDA (N-Methyl-*D*-aspartic acid or N-Methyl-*D*-aspartate), and AMPA (α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors, 3) catecholamine release and uptake, and 4) synaptic plasticity shown by long-term potentiation (LTP) and depression (LTD) in an NMDA receptor and PI3K dependent manner [26 - 29]. Insulin also promotes dendritic spine formation and excitatory synaptic development, and insulin regulates the development and health of excitatory synapses by activating PI3K/Akt/mTOR and Rac1/Cdc42 signaling [30].

Activation of the NMDA receptor recruits and activates neuronal NO synthase (nNOS) *via* Akt- and CaMKII(Ca^{2+} /calmodulin-dependent protein kinase II)-mediated phosphorylation of nNOS to promote the production of NO in the postsynaptic field [31, 32]. The activation of nNOS was also found to elevate AMPA receptor levels [32]. Thus, insulin can increase NO production in postsynaptic neurons by stimulating nNOS *via* activation of NMDA receptors. Increased NO promotes NADPH oxidase 2 (NOX2)-dependent ROS production postsynaptically, which may damage the dendritic field. Dendritic field destruction is one of the pathological changes in AD [33].

The importance of NO in modulating insulin receptor activity has also been illustrated by the blockade of the phosphatases SHP-1(Src homology region 2 domain-containing phosphatase-1), SHP-2(SH2 domain-containing protein tyrosine phosphatase-2), and PTP1B (Protein Tyrosine Phosphatase 1B) by S-nitrosylation of the cysteine residue at the enzyme's active sites concomitantly with a burst of NO production in response to insulin [34, 35]. Inhibition of the PTP1B, SHP-1, and SHP-2 by S-nitrosylation release inhibition of tyrosine phosphatases on insulin signaling. Hence, increased NO levels can promote NO-dependent tyrosine-phosphorylated insulin receptors and its downstream effector

Arginine, Nitric Oxide, and Type 2 Diabetes

Parvin Mirmiran^{1,2}, Zahra Bahadoran¹, Khosrow Kashfi³ and Asghar Ghasemi^{4,*}

¹ Nutrition and Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

² Department of Clinical Nutrition and Human Dietetics, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran

³ Department of Molecular, Cellular and Biomedical Sciences, Sophie Davis School of Biomedical Education, City University of New York School of Medicine, New York, NY 10031, USA

⁴ Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract: *L* Arginine (Arg), a semi-essential essential amino acid, has received significant research interest over the last two decades as nitric oxide (NO) precursor. Arg is widely used as a complementary treatment in various NO-disrupted conditions, e.g., hypertension, preeclampsia, and endothelial dysfunction. Here, we provide an overview of the potential efficacy of Arg as a NO precursor and its effects on glucose and insulin homeostasis and diabetes-induced cardiovascular complications.

Keywords: Arginine, Argininosuccinate lyase, Argininosuccinate synthase, Citrulline, Nitric oxide, Nitric oxide synthase, Ornithine aminotransferase, Ornithine transcarbamylase and ornithine decarboxylase, Type 2 diabetes.

INTRODUCTION

L-Arginine (Arg), a semi-essential or conditionally essential amino acid, is involved in synthesizing proteins, creatine, polyamines, agmatine, urea, and the metabolism of proline and glutamate in the body [1, 2]. Arg is provided by either the exogenous (dietary intake) or endogenous [*de novo* synthesis from *L*-citrulline (Cit) and turnover of proteins] sources; the sufficient magnitude of *de novo* synthesis makes Arg a non-essential amino acid in healthy adult humans. How-

* **Corresponding author Asghar Ghasemi:** Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Ghasemi@endocrine.ac.ir., No. 24, Erabi Street, Velenjak, Tehran, Iran; Phone: +98 21 22409309; Fax: +98 21 22416264.

ever, during early development and pathologic conditions, such as infection, inflammation, and impaired renal or intestinal metabolic functions, *de novo* synthesis is not sufficient to meet metabolic needs [3].

Arg has received significant research interest over the last two decades as nitric oxide (NO) precursor [1, 2]. This property has led to the widespread use of Arg as a complementary treatment in various NO-disrupted conditions, including hypertension [4 - 6], preeclampsia [7], and endothelial dysfunction [8]. Because of its ability to increase NO production, Arg has been considered a potential complementary treatment in type 2 diabetes (T2D) to improve glucose and insulin homeostasis and diabetes-induced cardiovascular complications [6, 8 - 10].

In this review, the potential efficacy of Arg as a NO precursor is discussed in T2D. First, we provide an overview of the amino acid metabolism (biosynthesis pathways, catabolic pathways, and pharmacokinetics of oral ingested doses) and its contributions to cellular and whole-body NO synthesis. Then, we provide some evidence to investigate the undesirable change of metabolism of Arg in T2D. Finally, the effects of supplementation with Arg on glucose and insulin homeostasis, and diabetes-related cardiometabolic complications, investigated in animal experiments and human clinical trials, are discussed.

PLASMA ARG FLUX

Plasma levels of Arg range from 80-120 μM in healthy adults [1]. Plasma flux of an amino acid represents the difference between arterial and venous concentrations of the amino acid multiplied by plasma flow; a positive value indicates net influx (uptake), and a negative value indicates net efflux [11]. Fluxes of plasma Arg in healthy humans on a normal diet were estimated to be 63-70 and 70-95 $\mu\text{mol/kg/h}$ in fasted and fed states, respectively [12, 13]; fed flux is higher because of increased entry of dietary Arg into plasma [14]. In healthy adults, about 10-15% (~ 5.5 - 9.2 $\mu\text{mol/kg/h}$) of the plasma Arg flux originates from *de novo* synthesis from Cit [12, 15]. Arg derived from protein turnover is ~ 36 $\mu\text{mol/kg/h}$ [16]. As indicated in Fig. (1), the endogenous flux of Arg in the fed state is lower than in the fasted state (52 v. 63 $\mu\text{mol/kg/h}$), probably because of the availability of Arg from exogenous sources, which decreases protein turnover and *de novo* synthesis of Arg.

Endogenous Arg flux, estimated after exclusion of dietary Arg intake from the plasma flux, remained unchanged following either free- and Arg-rich diets (~ 53 $\mu\text{mol/kg/h}$); contributions of protein breakdown and *de novo* synthesis of Arg were also similar in endogenous Arg flux in both conditions [16].




Fig. (1). Determinants of plasma flux of *L*-arginine (Arg). Both exogenous (10-30%) and endogenous sources (60-90%) contribute to Arg plasma flux. Created with BioRender.com.

The relative amount of Arg in various dietary proteins has been determined at 3-15% [17]. The usual daily intake of Arg in healthy adults has been estimated to be 4-6 g/day, which is ~20% of its plasma flux [18]. The contribution of diet to plasma Arg flux may be as low as ~8-20% in the fasted state (6-11 $\mu\text{mol/kg/h}$) to as large as ~35-40% in the postprandial state (~22-36 $\mu\text{mol/kg/h}$) [14, 16, 19]. Following a 6-day Arg-free diet, these values reduced to 52 ± 7 and 63 ± 14 $\mu\text{mol/kg/h}$, whereas, during the same period, an Arg-rich diet increased plasma Arg fluxes to 69 ± 8 and 87 ± 12 $\mu\text{mol/kg/h}$ in the fasted and fed states, respectively [16]. Fig. (1) displays determinants of plasma Arg flux.

Arginine Biosynthesis Pathways

A significant fraction of Arg is synthesized from the amino acid Cit through an intestinal-renal axis. About 50-80% of Cit released by the intestine is taken up by the kidneys [20, 21] and then converted into Arg within the proximal tubule *via* argininosuccinate synthase (ASS) and argininosuccinate lyase (ASL) enzymes (Fig. 2); about 75% [22] to 100% [20] of plasma Cit taken up by the kidney backs into the circulation as Arg. The extra-renal tissues are also involved (up to 40%) in Arg *de novo* synthesis for both meeting their needs for Arg and its release into circulation; in the nephrectomized mouse model (~80% nephrectomy), the amount of Cit accounted for plasma Arg decreased from 88 to 42% [23].

Citrulline, Nitric Oxide, and Type 2 Diabetes

Parvin Mirmiran^{1,2}, Zahra Bahadoran¹, Khosrow Kashfi³ and Asghar Ghasemi^{4,*}

¹ Nutrition and Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

² Department of Clinical Nutrition and Human Dietetics, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran

³ Department of Molecular, Cellular and Biomedical Sciences, Sophie Davis School of Biomedical Education, City University of New York School of Medicine, New York, NY10031, USA

⁴ Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract: L-citrulline (Cit), a neutral, non-essential, and non-protein amino acid, is a precursor of L-arginine (Arg) and is involved in nitric oxide (NO) synthesis. Since oral ingestion of Cit can effectively elevate total Arg flux in the entire body and promote NO production, its supplementation has recently received much attention in the realm of cardio-metabolic diseases where NO metabolism is disrupted. Although preliminary data obtained from *in vitro* and *in vivo* animal experiments indicates that Cit improves glucose and insulin homeostasis and can effectively prevent hyperglycemia-induced complications such as inflammation, oxidative stress, renal dysfunction, and endothelial dysfunction, these findings are yet to be realized in well-designed long-term clinical studies in patients with type 2 diabetes (T2D). If Cit is shown to be an effective anti-diabetic agent with a good safety profile, its supplementation will be superior to that of Arg because it effectively increases systemic Arg availability more than Arg itself, and hence NO production.

Keywords: Arginine, Arginase, Argininosuccinate Synthase, Argininosuccinate Lyase, Carbamoyl Phosphate Synthetase I, Citrulline, Glutamine, Nitric Oxide, Ornithine Decarboxylase, Ornithine Transcarbamylase, Type 2 Diabetes.

* Corresponding author **Asghar Ghasemi**: Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran; No. 24, Erabi Street, Velenjak, Tehran, Iran; Phone: +98 21 22409309; Fax: +98 21 22416264, Email: Ghasemi@endocrine.ac.ir

INTRODUCTION

L-Citrulline (Cit) is a neutral, non-essential, non-protein amino acid, which is best known as an intermediate in the urea cycle but has also garnered interest as a precursor of *L*-arginine (Arg) synthesis and nitric oxide (NO) production [1]. The name of this amino acid originated from the *Citrullus vulgaris* (watermelon); it was first isolated in 1914 from watermelon juice, but it was not until 1930 when Mitsunori Wada elucidated its structure and named it ‘citrulline’ [2]. Due to its relatively rare food sources (fresh watermelon containing about 1.6-3.5 g/kg), the amount of Cit provided through usual dietary intakes is somewhat limited. For example, one has to consume about 1-1.5 kg of fresh watermelon to achieve the minimum effective dose of Cit, which is about 3 g [3]. Watermelon rind contains more Cit than flesh watermelon, approximately 24.7 *versus* 16.7 mg/g dry weight [4]. There is no recommended dietary allowance for Cit [1].

The mean plasma concentration of Cit has been reported to be about 20-47 μM [5 - 10], and whole body Cit flux is estimated to be $\sim 8.9 \mu\text{mol/kg/h}$ (~ 6 -10 $\mu\text{mol/kg/h}$), in healthy human adults in the fasted state [5]. More quantitatively, whole body Cit flux has been estimated to be about 4g/day [11]. The mean concentration of Cit in red blood cells (RBC) was reported as approximately $31 \pm 13 \mu\text{M}$ [10]. Cit is the only precursor of Arg *de novo* synthesis in the body; the conversion of Cit into Arg occurs in the kidneys, endothelial, and immune cells, as exemplified by activated macrophages [12]. Several studies indicate that Cit raises plasma Arg concentrations and effectively promotes whole-body NO production [3, 12, 13]. Cit augments NO-dependent signaling pathways and exerts beneficial effects in pathologic conditions relating to reductions in NO availability, such as cardiovascular disease and hypertension [3, 12, 13].

Cit appears much more effective than Arg for NO production [14]. Furthermore, oral doses of Arg impose some negative effects, including induction of arginase activity [15, 16] and urea production [17], inhibition of cellular uptake of Cit [18] and recycling of Arg from Cit [16], suppression of endothelial NO synthase (eNOS) expression and activity [19], and induction of cellular oxidative stress [19]. On the other hand, there is evidence indicating the existence of cellular “Arg tolerance” with long-term Arg exposure, a phenomenon that reduces the expected beneficial effects of long-term Arg supplementation [19]. For such reasons, Cit has recently received more attention than Arg as a NO-boosting supplement.

This chapter provides an overview of Cit metabolism in the body and its role in whole-body NO production. Then we discuss the efficacy and safety of oral doses of Cit in type 2 diabetes (T2D), a pathological condition of NO-disrupted metabolism.

CIT BIOSYNTHESIS PATHWAYS

Cit biosynthesis is a complex process and involves multiple precursors, enzymes and intracellular, and interorgan substrates transfer. Cit biosynthesis occurs in both the intestine and intra-intestine organs; intestinal biosynthesis is estimated to be responsible for 60-90% of whole plasma Cit flux, whereas extra-intestinal biosynthesis provides a fraction of Cit flux estimated to be as low as 10-30% [20].

Intestinal Biosynthesis of Cit

The intestine is the principal site of Cit biosynthesis, and it is the organ that supplies the entire body with Cit [20]. Enteral or plasma amino acids such as Arg, glutamine, glutamate, and proline are responsible for supplying the ornithine used for Cit biosynthesis in the enterocytes [21, 22]. The enzymes involved in the synthesis of ornithine are glutaminase, pyrroline-5-carboxylate synthase, proline oxidase, arginase, and ornithine aminotransferase (OAT), the latter being the key enzyme [21]. The ornithine is finally converted into the Cit by the action of ornithine transcarbamylase (OTC), one of the key enzymes in the urea cycle, which in humans is mainly present in the liver and intestinal mucosa [9]. The presence of the urea cycle enzymes, which are carbamoyl phosphate synthetase I (CPS-I), ornithine decarboxylase (ODC), arginase, argininosuccinate synthase (ASS), and argininosuccinate lyase (ASL) in the enterocytes, provides a biochemical basis for synthesizing Cit and Arg from glutamine [23, 24].

The kinetic properties of the intestinal urea cycle enzymes, optimizing the net synthesis of Cit from glutamine, can explain the large amounts of Cit that are released by the intestine. First, compared to the liver, the intestinal urea cycle enzymes are likely to synthesize Cit rather than urea; second, co-localization of CPS-I and OCT, along with a high activity of OCT in the mitochondria, enables the enterocytes to synthesize Cit from ammonia, HCO_3^- and ornithine; and third, low activities of the cytosolic ASS and ASL minimize the Cit-Arg conversion and the recycling of Cit into ornithine *via* arginase in the enterocytes [25].

The extent of contribution of each of the amino acids glutamine, Arg, and proline to the intestinal biosynthesis of Cit is under debate. Initial investigations suggested glutamine as an important precursor (60-80%) for plasma Cit in humans [26, 27]. In healthy adults in the fed state, more than 70% of the ^{15}N label glutamine was found on the α -nitrogen of Cit [5]. About 13-26% of glutamine taken up by the intestines is converted to Cit [27], and the conversion rate has been estimated to be about $5.1 \pm 0.7 \mu\text{mol/kg/h}$ [27]. A significant association is observed between Cit flux and plasma glutamine concentration ($r = 0.78$) [5].

Nitrate, Nitrite and Type 2 Diabetes

Zahra Bahadoran¹, Parvin Mirmiran^{1,2}, Khosrow Kashfi³ and Asghar Ghasemi^{4,*}

¹ Nutrition and Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

² Department of Clinical Nutrition and Human Dietetics, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran

³ Department of Molecular, Cellular, and Biomedical Sciences, Sophie Davis School of Biomedical Education, City University of New York School of Medicine, New York, NY10031, USA

⁴ Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract: Recent research punctuates that the nitrate (NO₃)-nitrite (NO₂)-nitric oxide (NO) pathway may be a potential therapeutic target in type 2 diabetes (T2D), a NO-disrupted metabolic disorder. Nutritional aspects of the NO₃-NO₂-NO pathway has been highlighted by focusing on the protective effects of some traditional high-NO₃ diet, such as Mediterranean and DASH (Dietary Approaches to Stop Hypertension) diets and their NO₃-rich components, *i.e.*, fruits, vegetables, legumes, and green leafy vegetables, against the development of T2D. Both acute and long-term administration of inorganic NO₃ and NO₂ in animal experiments display anti-diabetic properties; inorganic NO₃ decreases fasting blood glucose, glycosylated hemoglobin, and proinsulin to insulin ratio and improves glucose tolerance. In contrast to animal experiments, NO₃/NO₂ therapy has failed to show anti-diabetic properties and beneficial effects on glucose and insulin homeostasis in humans. This lost-i-translation remains an open question, and long-term clinical trials are needed to confirm the salutary effects of inorganic NO₃ and NO₂ as the natural NO boosters in patients with T2D.

Keywords: Acceptable Daily Intake, Insulin Resistance, Hypertension, Metabolic Syndrome, Nitric Oxide, Nitric Oxide Synthase, Nitrate, Nitrite, Type 2 Diabetes.

* **Corresponding author Asghar Ghasemi:** Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran; No. 24, Erabi Street, Velenjak, Tehran, Iran; Phone: +98 21 22409309; Fax: +98 21 22416264, Email: Ghasemi@endocrine.ac.ir

INTRODUCTION

Inorganic nitrate (NO_3) and nitrite (NO_2) can act as a substrate or backup system for non-enzymatic endogenous generation of nitric oxide (NO), and current data indicate that both NO_3 and NO_2 display NO-like bioactivity [1, 2]. The ability of inorganic NO_3 - NO_2 to convert to NO highlights the physiological importance and novel aspects of the pathway in health and disease [3]. Boosting the NO_3 - NO_2 -NO pathway, where the classic L-arginine-NO pathway is compromised, has therefore become an attractive approach for potential prevention and treatment of cardiometabolic diseases, including hypertension (HTN), metabolic syndrome (MetS), and T2D [4, 5].

Both *in vitro* and *in vivo* animal experiments greatly support the hypothesis that the NO_3 - NO_2 -NO pathway plays a critical role in regulating glucose and insulin metabolism and insulin signaling [6 - 8]. Supplementation with inorganic NO_3 - NO_2 in animal models of T2D resulted in improved hyperglycemia, insulin sensitivity, and glucose tolerance; their supplementation was also accompanied by elevated pancreatic islet insulin content and insulin secretion, improved inflammation, dyslipidemia, liver steatosis, and oxidative stress [9 - 11]. Favorable effects of NO_3 therapy on glucose and insulin homeostasis have been reported to be head-to-head with metformin, the first-line anti-diabetic agent [12]. In animal experiments, NO_3 had equipotent anti-diabetic effects compared to metformin, while it was superior to protecting against diabetes-induced cardiovascular dysfunction and liver steatosis [12].

Although the beneficial effects of inorganic NO_3 - NO_2 supplementation have received increasing appreciation in animal experiments, their efficacy on glucose and insulin homeostasis has remained unproven in humans. Supplementation with inorganic NO_3 and NO_2 (as KNO_3 , NaNO_3 , NaNO_2 , or NO_3 -rich food products) in acute [13], mid-term [14, 15], and long-term [16 - 18] experiments, have failed to show beneficial effects on glucose and insulin parameters including fasting and postprandial plasma glucose and insulin, insulin resistance indices, and HbA1c levels in patients with T2D.

This chapter reviews available data, animal experiments and human clinical trials, addressing the potential effects of inorganic NO_3 / NO_2 on glucose and insulin homeostasis in T2D. We also try to provide some plausible reasons to address the challenge of lost-in-translation of beneficial effects of inorganic NO_3 and NO_2 from bench-to-bedside.

INORGANIC NITRATE AND NITRITE: A NUTRITIONAL PERSPECTIVE

Due to the historical background about potential hazardous effects of inorganic NO_3 and NO_2 [19, 20], strict regulations and limitations have been legislated for exogenous exposure of NO_3 - NO_2 from both dietary intake and drinking water [21]. In 1975, US Environmental Protection Agency (EPA) established the maximum contaminant level for NO_3 at 10 mg/L, and in 1993, the world health organization (WHO) established the maximum concentration limit as 11.3 mg/L nitrate-nitrogen in drinking water; the permissible NO_3 level in drinking water is now 50 mg/L in the European Union and 44 mg/L in the US [22]. The acceptable daily intake (ADI) values are 3.7 and 0.06 mg/kg body weight for NO_3 and NO_2 , respectively [22]. The acute oral LD_{50} values of sodium nitrate (NaNO_3) in rats, mice, and rabbits were reported in a range of 2480-9000 mg/kg; for sodium nitrite (NaNO_2), these values range 180-214 mg/kg in rats, rabbits, and mice [23].

Food and Dietary Sources of Inorganic NO_3 and NO_2

The main dietary sources of inorganic NO_3 are vegetables, especially green leafy vegetables, beetroot, and celery [24]. The NO_3 levels of vegetables are commonly categorized as low (<100 mg/kg), medium (100-1000 mg/kg), and high- NO_3 (>1000 mg/kg) [25, 26]. Celery, mint, lettuce, tarragon, beetroot, and radish are considered very-high NO_3 -containing vegetables, while scallion, cauliflower, zucchini, eggplant, parsley, leek, dill, spinach, cabbage, turnip, cress, and basil are classified as high NO_3 -containing vegetables [27]. Other vegetables, including carrots, onions, mushrooms, fenugreek, cucumber, and green pea, contain a medium level of NO_3 , whereas corn, garlic, potato, green beans, and tomato are categorized as low- and very low- NO_3 vegetables [27]. A recent systematic search reviewed 255 published documents (1980-2016) on NO_3 content of vegetables database, reported that NO_3 content of vegetables ranged from Chinese flat cabbage (median=4240, range= 3004-6310 mg/kg of fresh weight) to corn (median=12; 5-1091 mg/kg of fresh weight) [24].

The NO_2 content of vegetables has been reported in a range of less than 1 mg/kg, however in some Asian countries (*e.g.*, Iran, Japan, Turkey, and South Korea), NO_2 contents of vegetables were reported to be in a wide range of 1.7-7.4 mg/kg [27 - 30]. European countries usually report a lower range of NO_2 content in vegetables to be 0.1-2.5 mg/kg [30]; however, some countries, *e.g.*, Denmark and Germany, reported a maximum level of 11.0 and 19.6 mg/kg, respectively [30]. In some reports, NO_2 concentrations ranged between 1.1-54 mg/kg [31]; a wide range of NO_2 levels were reported in vegetables especially in lettuce (2.9-8.8 mg/kg), spinach (3.8-12.7 mg/kg), and radish (2.4-14.2 mg/kg) [32]. Several

Potential Applications of Nitric Oxide Donors in Type 2 Diabetes

Zahra Bahadoran¹, Parvin Mirmiran^{1,2}, Mehrnoosh Bahmani³ and Asghar Ghasemi^{4,*}

¹ Nutrition and Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

² Department of Clinical Nutrition and Human Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran

³ Ontario College of Pharmacist, University of Waterloo School of Pharmacy Alumni, Waterloo, Ontario, Canada

⁴ Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract: Nitric oxide (NO) donors are chemical agents that produce NO-related activity in biological systems, mimic endogenous NO-related responses, or compensate for NO deficiency. NO donors have been increasingly studied as promising therapeutic agents for insulin resistance and type 2 diabetes (T2D). Here, we provide evidence, which investigated the effects of the most frequently studied and implemented NO-releasing compounds, including sodium nitroprusside (SNP), S-nitrosothiols [RSNOs, *i.e.*, S-nitrosoglutathione (GSNO), S-nitroso-N-acetyl-penicillamine, (SNAP)], and N-Diazeniumdiolates (NONOates, *i.e.*, spermine NONOate, diethylamine NONOate) on glucose and insulin homeostasis. Available evidence could not draw a clear conclusion regarding therapeutic applications of NO donors in T2D due to different methodological approaches (*i.e.*, *in vitro* vs. *in vivo*) and different doses and formulations used to assess the potential effects of NO donors on carbohydrate metabolism. Considering key properties and different kinetic behaviors between various classes of NO donors, targeted compound selection, defining optimum doses, and appropriate use of NO-releasing platforms (topical vs. systemic delivery mode) seem to be critical issues that can accelerate the bench-to-beside translation of NO donors in T2D.

* **Corresponding author Asghar Ghasemi:** Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Ghasemi@endocrine.ac.ir., No. 24, Erabi Street, Velenjak, Tehran, Iran; Phone: +98 21 22409309; Fax: +98 21 22416264.

Keywords: Diethylamine NONOate, Insulin resistance, *N*-Diazoniumdiolates, Nitric oxide, Nitric oxide donors, Nitroprusside, Sodium nitroprusside, *S*-nitrosoglutathione, *S*-nitrosothiols, *S*-nitroso-*N*-acetyl-penicillamine, Spermine NONOate, Type 2 diabetes.

INTRODUCTION

Impaired nitric oxide (NO) homeostasis and function are associated with the development of insulin resistance and type 2 diabetes (T2D) [1]. As discussed in Chapter 3, reduced NO production [due to impaired *L*-arginine-NO synthase (NOS) pathway [2] and the nitrate (NO₃)-nitrite (NO₂)-NO pathway [3, 4], inducible NOS (iNOS)-induced overproduction of NO [5], impaired NO transport within the circulation and its delivery to target cells, reduced NO availability [*e.g.*, *via* oxidative-induced NO quenching [6, 7], and impaired NO signaling pathway [*i.e.*, NO-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway [8, 9] contribute to impaired NO bioactivity in hyperglycemia and insulin resistance.

To overcome the impaired NO homeostasis and increase NO bioactivity, several therapeutic approaches, including supporting NO precursors for both NOS and NO₃-NO₂-NO pathways (see Chapters 12, 13, 14), providing co-factors of cNOS (*e.g.*, tetrahydrobiopterin, BH₄) [10], targeted-inhibition of iNOS [11, 12], using sGC activators [13, 14] (ongoing clinical trials: NCT03091920 and NCT02906579), restoring NO bioavailability and its function by antioxidants [15, 16] have been evaluated in NO-disrupted situations like T2D [17 - 19]. Using NO donors, *i.e.*, chemical substances that generate NO *via* NOS-independent mechanisms [20], has been increasingly studied as a promising NO-based therapeutic approach in T2D.

As a brief history, the first NO donor, glyceryl trinitrate (GTN), has been clinically used for 150 years for acute angina pectoris [21]. However, it was first recognized as a NO donor in the 1980s [21]. Glyceryl trinitrate was synthesized by an Italian chemist, Ascanio Sobrero, in 1847; however, its *in vivo* mechanism of action remained unknown until the discovery of NO as a naturally occurring messenger molecule in the 1980s [22]. The second most-known NO donor, sodium nitroprusside (SNP), was initially discovered in 1849 by Playfair [23] and was initially used as an anti-hypertensive agent by Johnson in 1922 [24]. In 1979, it was revealed that SNP acts *via* NO in the bovine coronary artery, where NO activates guanylate cyclase, resulting in vascular relaxation through cyclic guanosine monophosphate (cGMP) production [25].

During the past two decades, the development of influential NO donors and advanced NO-releasing materials for clinical therapies has been a significant

research interest [26 - 31]. Several synthetic compounds have been developed to chemically stabilize and release NO, in a controlled manner [27, 29, 32]. As exposure time with NO and its kinetic behavior critically affect NO biological applications, researchers have tried to develop various NO donors, mimicking continuous NO production in a wide range of time intervals from seconds to days [27, 33]. On the other hand, despite the simplicity of the chemical nature, exogenous applications of NO are challenging due to the complex reactions in which NO is involved, tissue specificity, and concentration-dependence behaviors of the molecule [34].

This chapter gives a brief overview of NO donors and provides evidence that investigated the effects of the most frequently studied and implemented NO-releasing compounds (*i.e.*, SNP and S-nitrosothiols) on carbohydrate metabolism.

A BRIEF OVERVIEW OF NITRIC OXIDE DONORS

Nitric oxide donors are a heterogeneous group of compounds able to release NO-related species, including NO radical, the nitrosonium ion (NO⁺), or the nitroxyl anion (NO⁻), *in vitro* or *in vivo*, independently of its endogenous sources [35]. However, there is a substantial difference between the compounds as to which NO-related species (*i.e.*, NO⁺, NO radical, or NO⁻) they release in biological systems (See Box. 1); the reactivity towards other biomolecules, the produced by-products, and the response are affected by different NO-related species released by donor compounds [36]. No clear-cut definition has been provided for NO donors; some definitions have restricted NO donors to those generating NO through mechanisms that are independent of the enzymatic action of NOSs [20] and endogenous sources [35], while others discussed that the term NO donor implies on the compound releases the active NO [36], thus included *L*-arginine and inorganic NO₃ and NO₂ as NO donors [34, 37].

Nitric oxide donors have been classified according to different points of view, including their chemical structures of NO-releasing moieties, the form of NO released by the compound (*e.g.*, NO donors *vs.* HNO donors), the mode of actions (*i.e.*, spontaneously released or those required metabolic activations), and their typical working mechanisms [35, 38 - 40]; furthermore, others classified NO donors as natural *vs.* synthetic donors [34], exogenous *vs.* endogenous stimuli sensitive donors [28], and short- *vs.* long-acting NO donors [41]. The American Chemical Society comprehensively reviewed nomenclatures and major classes of NO donors in 2002 [20]. Table 1 provides a brief overview of the most common NO donors [20, 30, 31, 42 - 49]. The most frequently employed NO donors in basic and clinical studies are organic nitrates (*e.g.*, glyceryl trinitrate, isosorbide dinitrate), SNP [Na₂(FeCN)₅NO], sydnonimines [*e.g.*, molsidomine, morpholino-

SUBJECT INDEX

A

- Absorption 212, 221, 267, 331
 drug 331
 intestinal 267
 intestinal glucose 212
 Acarbose therapy 221
 Acceptable daily intake (ADI) 303, 305, 306
 Acid(s) 10, 18, 19, 79, 49, 50, 52, 53, 89, 134,
 136, 139, 148, 190, 191, 192, 193, 194,
 196, 198, 199, 200, 201, 202, 214, 217,
 223, 238, 240, 286, 316, 317, 314, 330
 ascorbic 52, 53, 223, 317
 citric 148
 dehydroascorbic 53
 fatty 19, 79
 free fatty (FFA) 10, 18, 19, 49, 50, 214,
 217, 314
 glycyrrhetic 330
 glycyrrhizin 330
 hyaluronic 134
 lipoteichoic 139
 neutralization 89
 opionic 238
 organic 89
 pionic 240
 plasma amino 286
 producing bacteria 89
 skin conditions 136
 uric (UA) 190, 191, 192, 193, 194, 196, 198,
 199, 200, 201, 202, 316
 Acidified nitrite cream 145
Actinobacillus actinomycetemcomitans 95
Actinomyces odontolyticus 92
 Activating protein kinase 50
 Activation 49, 50, 130, 131, 163, 168, 171,
 199, 201, 239, 240, 242, 243, 244
 insulin-induced 199
 Activity 8, 9, 43, 44, 46, 49, 50, 67, 69, 89,
 109, 113, 115, 116, 139, 147, 163, 167,
 192, 224, 242, 243, 245, 246, 289, 295,
 328, 330, 338
 analgesic 330
 anti-inflammatory 89
 antimicrobial 109, 139
 antitumor 330
 enzymatic 115, 245, 246
 inflammatory 242
 macrophage 295
 mitochondrial aconitase 43
 neuroelectrophysiological 243
 neuronal 243
 robust hypoglycaemic 224
 uricase 192
 vasodilatory 328
 xanthine oxidase 193
 Adenosine deaminase 192
 Adipogenesis 169, 172
 Adipose tissue 7, 8, 16, 17, 41, 43, 44, 45, 97,
 201, 309, 310, 311, 313, 314
 fibrosis 44
 ADMA 68, 69, 70, 71, 73, 79, 266, 296
 biosynthesis and metabolism 69
 catabolism 266
 DDAH pathway 73
 incubated porcine coronary artery
 endothelium 296
 metabolism 68, 69, 70, 79
 residues in protein hydrolysates 71
 ADMA-dimethylarginine68
 dimethylaminohydrolase 68
 Aerobic conditions 90
 Agents 28, 79, 132, 172, 192, 238, 294, 308
 anticancer 192
 chemoattractant 132
 endothelium-dependent relaxing 28
 insulin-sensitizing 79, 294
 natural compensatory 308
 oral anti-diabetic 79
Aggregatibacter actinomycetemcomitans 95
 Alanine transaminase 316
 Alpha-glucosidase inhibitors (AGIs) 210, 212,
 221
 Alzheimer's disease 238, 239, 241, 242, 246

Subject Index

Amino acid(s) 6, 68, 89, 110, 260, 261, 262, 266, 267, 284, 285, 286, 289
extracellular cationic 266
glutamine 286
non-protein 284, 285
Aminoguanidine 171, 214
Aminotransferases 69, 77, 289
alanine glyoxylate 77
Ammonia oxidizing bacteria (AOB) 136, 137
AMP 9, 46, 171, 193, 197, 202, 212, 249, 309
activated protein kinase 9, 46, 171, 197, 202, 212, 309
deaminase 193
kinase 249
AMPK 213, 294, 339
activity 339
induced eNOS activation by metformin 294
mediated mechanism 213
phosphorylation 213
Amyloid angiopathy 246
Angina 27, 30
treating 27
Angina pectoris 31, 327, 328
treating 31
Angiogenesis 128, 129, 133, 135, 139, 140, 141, 142, 143, 163
stimulating 133
Angiogenesis processes 143
Antibacterial 93, 94, 128, 129, 337
mouthwash 93, 94
properties 128, 129
Anti-carcinogenesis actions 337
Anti-diabetic 284, 303, 317
agent, effective 284
properties 303, 317
Anti-inflammatory drugs 327, 330
non-steroid 330
Anti-inflammatory properties 330
Antimicrobial 139, 140, 143, 144
properties 144
therapy 139
treatment 143
Antioxidant 50, 145, 148, 194, 325
defense 145
defense mechanisms 148

The Role of Nitric Oxide in Type 2 Diabetes 351

responsive elements 50
Antisense oligonucleotides 247
Antiseptic mouthwash 93, 94
chlorhexidine 94
Antithrombotic properties 328
Apolipoprotein 314
Apoptosis 52, 129, 132, 134, 163
Arginase 51, 52, 138, 263, 263, 264, 265, 268, 270, 271, 274, 284, 286, 290, 291
expression 291
hepatic 263
mitochondrial 268
pathway 138, 264
Arginase activity 49, 173, 199, 265, 270, 285, 289, 295, 296, 267
elevated 296
hepatic 267
intestinal 267
pathological elevated 295
Arginine 262, 263
biosynthesis pathways 262
catabolic pathways 263
decarboxylase 263
glycine transaminase 263
Argininosuccinate lyase 260, 262, 263, 284, 286, 288
Argininosuccinate synthase 260, 262, 263, 284, 286, 288
Arg 70, 261, 285
methylation 70
on glucose and insulin homeostasis 261
tolerance 285
Arg metabolism 263, 271
dysregulated 271
Arg supplementation 270, 271, 272, 273, 274, 275
oral 273
in metabolic syndrome 273
Aspartate transaminase 316
Astrocytes 245
Atherogenesis 15
Atheroprotection 216
Atherosclerosis 68, 75, 131, 194, 211, 314
aortic 314
carotid 194

macrovascular 75
 ATP 9, 11, 193, 213, 215
 dependent potassium channels 11
 depletion 193
 production 9, 213
 sensitive potassium 215
 Autophosphorylation 199, 242

B

Bacteria 88, 89, 90, 91, 93, 94, 95, 132, 137, 140, 144, 149, 223
 acid-degrading 89
 ammonia-oxidizing 137
 anaerobic 88, 90, 93
 antibiotic-resistant 144
 hyperglycemia-related 95
 pathogenic 88
 Beetroot juice 94, 314, 316
 Biological actions 331
 Biosynthesis, intestinal 286, 288
 Bisphosphonates 171, 173
 Blood 12, 45, 133, 222, 270, 290, 332, 338
 glucose concentration 338
 human peripheral 332
 Blood pressure 93, 99, 214, 219, 223, 222, 224, 269, 272, 273, 309, 312, 314, 315, 316, 328, 333
 arterial 333
 diastolic 222, 224, 272, 273
 systolic 328
 Bone 161, 162, 164, 165, 166, 167, 169, 170, 172, 173
 fractures 167
 microarchitecture 161
 mineral density (BMD) 161, 164, 172, 173
 morphogenetic protein-2 165, 166
 remodeling signals 169
 resorption, osteoclast-mediated 161, 162, 165, 167, 169, 170, 173
 Bone formation 161, 162, 163, 165, 167, 168, 169, 170, 172, 173
 osteoblastic 163

osteoblast-mediated 161, 162, 165, 167, 169, 173
 Bone marrow 140, 143, 161, 165, 166, 169
 adiposity 161, 166
 eNOS phosphorylation 143
 Bovine 31, 51, 72, 78, 295
 aortic endothelial cells (BAECs) 31, 51, 72, 78, 295
 coronary artery 325
 Brain insulin signaling 241, 243, 247, 248
 defects 247
 Brain stimulation 7
 Breakdown 70, 221, 337
 ion-dependent 337
 proteolytic 70
 Brown adipose tissue (BAT) 9, 43, 45, 46

C

Calcium-releasing agent 333
Candida albicans 90
 Capacity 12, 43, 43, 44, 45, 194, 267, 291, 292, 306, 314, 317
 mitochondrial 43, 45
 radical-scavenging 194
 Capnocytophaga 95, 96
 Carbohydrate(s) 39, 42, 89, 97, 111, 112, 201, 221, 324, 326, 337, 338, 340
 complex non-absorbable 221
 metabolism 39, 42, 97, 111, 112, 201, 324, 326, 337, 338, 340
 metabolizers 89
 Cardiac 4, 112
 arrhythmias 4
 hypertrophy 112
 Cardiobacterium 95, 96
 Cardiocerebrovascular events 173
 Cardiometabolic disorders 88, 113, 194, 308
 Cardiomyocytes 190, 191, 197
 Cardioprotective activity 330
 Cardiovascular
 diseases 67, 68, 76, 77, 108, 190, 191, 194, 195, 211, 214, 215, 224, 307, 308

Subject Index

events 76, 215, 224
Catabolism 191, 192, 268
 guanine-based purines 191
Catalase 314
Cellular proteins 68, 70
 methylated 68
Central nervous system (CNS) 6, 7, 8, 46, 239
Chronic 53, 130, 190, 191, 274, 307
 aortic regurgitation 274
 gastritis 53
 ischemia 130
 kidney disease (CKD) 190, 191, 307
Citrullus vulgaris 285
Cognitive 238, 241, 243, 314
 deficits 238
 function 241, 243, 314
Collagenase 169
Collagen 128, 129, 133, 138, 141, 144, 145,
 146, 147, 148, 149, 150, 165
 deposition 128, 129, 133, 138, 144, 145,
 146, 147, 148, 149, 150
 synthesis 138, 141, 146, 165
Colorectal cancer 307
Combination therapy 214, 219
Commensal 53, 88, 94, 223
 bacteria 94, 223
 oral 53, 88
Commensalism 88
Communities 53, 88, 90, 92, 93
 dynamic microbial 88
 oral bacterial 93
Compartmentalization of arginase 263
Complementary addition 294
Contraction signaling pathways 334
Conversion 44, 223, 265, 267, 285, 287, 290,
 291
 gastric 223
 impaired metabolic 287
Coronary 68, 75, 108, 195, 211, 220
 angioplasty 220
 artery disease 108, 211
 heart disease (CHD) 68, 75, 195
Cortisol manipulation 240
Cutaneous 145, 147
 eNOS protein expression and activity 145

The Role of Nitric Oxide in Type 2 Diabetes 353

 gene therapy 147
Cyclooxygenase 49, 50, 329
Cystic fibrosis transmembrane regulator
 (CFTR) 9
Cytochrome 32, 52, 90
Cytokines 48, 72, 96, 109, 131, 132, 133, 135,
 139, 163, 164, 168, 192, 197
 induced cells 109
 inflammatory 192, 197
 pro-inflammatory 48, 72, 96, 139, 163

D

Damage, diabetic kidney 215
Death, cardiovascular 76
Defects 16, 17, 109, 247, 249, 272
 immune 109
 insulin secretory 247
 systemic insulin signaling 249
Deformities 130
Degradation 69, 134, 141, 338
 inhibited insulin 338
Dementia 238, 239, 243, 248
Dendritic field destruction 240
Denitrification pathway 93
Depletion 6, 49, 50, 51, 137, 199, 287
 liver glycogen 6
Dermis reconstruction 145, 148
 accelerating 148
Diabetes 2, 97, 219, 261, 309
 pathogenic mechanisms linking 97
 diagnosis 2
 of hepatic glucose 219
 related cardio-metabolic abnormalities 309
 related cardiometabolic complications 261
Diabetic 3, 44, 118, 119, 128, 129, 130, 135,
 143, 144, 275, 338
 foot ulcer (DFU) 128, 129, 130, 143, 144
 ketoacidosis 3
 medication 224
 nephropathy (DN) 44, 118, 119, 275, 338
 wound homogenates 135
Diabetic retinopathy 75, 76, 113
 non-proliferative 75

- proliferative 75
 - Diabetic wounds 128, 129, 132, 133, 134, 135, 141, 142, 143, 144, 148, 150
 - infected 144
 - Diabetoporosis 161, 162, 166, 167, 170, 171, 172, 173
 - Diastolic blood pressure (DBP) 222, 224, 272, 273
 - Dietary supplements 79, 274
 - Differentiation, osteoblastic 163
 - Dimethylaminohydrolase 67
 - Diseases 1, 17, 68, 75, 89, 113, 143, 194, 195, 238, 239, 241, 242, 249, 284, 269, 294, 304, 306
 - age-related neurodegenerative 238
 - autoimmune 194
 - cardio-metabolic 284
 - coronary heart 68, 75, 195
 - inflammatory bowel 113
 - neurodegenerative 242
 - non-communicable 1
 - Disorders 18, 247, 306, 309, 338
 - diabetes-induced cardio-metabolic 309
 - neurodegenerative 247
 - thyroid 306
 - DNA 70, 295
 - damage 295
 - repair 70
 - Downregulates 50
 - Downstream signaling 194, 243, 244
 - cascades 244
 - effects 194
 - Drugs 79, 170, 171, 172, 173, 210, 212, 214, 215, 216, 217, 219, 221, 222, 223, 317, 329
 - anti-diabetic 79, 170, 171, 172, 317
 - anti-hyperglycemic 215
 - anti-osteoporotic 171, 172
 - developing NO-releasing 329
 - hybrid 329
 - insulin-sensitizing 294
 - Dysbiosis 15, 53, 88, 89, 90, 93, 98, 99
 - oral 53, 88, 89, 90, 98, 99
 - Dysfunction 4, 16, 29, 31, 68, 108, 167, 194, 195, 265, 270, 275, 284
 - diabetes-induced cardiovascular 304
 - managing erectile 29, 32
 - neurological 4
 - neuronal 243
 - neurotransmitter 16
 - renal 68, 284
 - thyroid 195
 - vascular 108, 194, 265, 270, 275
 - Dysfunctionality 49, 51
 - diabetes-induced 51
 - Dysglycemia 39, 53, 73, 95, 190, 191
 - hyperuricemia-induced 190, 191, 198, 199
 - Dyslipidemia 15, 112, 119, 191, 304, 314
 - Dysregulation 52
- E**
- Effects 138, 139, 150, 172, 194, 213, 214, 215, 224, 304, 308
 - anorexic 213
 - antibacterial 150
 - antidiabetic 224
 - anti-diabetic 304, 308
 - antilipidemic 214
 - antimicrobial 139
 - anti-osteoporotic 172
 - arginine-mediated 138
 - chondroprotective 194
 - hypoglycemic 215
 - Empagliflozin 221, 222
 - Endocrine hormone 40, 88, 107
 - Endogenous 4, 5, 6, 7, 10, 271, 288
 - biosynthesis 288
 - glucose production (EGP) 4, 5, 6, 7, 10, 271
 - Endometriosis 195
 - Endothelial cells 28, 31, 51, 68, 69, 72, 109, 110, 140, 190, 191, 199, 201, 215, 265, 266, 295, 335
 - bovine aortic 31, 51, 72, 295
 - human aortic 215
 - vascular 335
 - Endothelial dysfunction 69, 73, 79, 215, 219, 222, 224, 242, 260, 261, 266, 294, 295

Subject Index

Endothelial nitric oxide synthase 18, 27, 39, 67, 107, 128, 130, 161, 167, 170, 246
Endothelial progenitor cells (EPCs) 133, 140, 143, 273
Endothelium 27, 29, 30, 31, 32
 dependent relaxation 31
 derived relaxing factor (EDRF) 27, 29, 30, 31, 32
End-stage renal disease (ESRD) 118
Environmental protection agency (EPA) 305
Enzymatic denitrosation 29, 32
Enzyme(s) 12, 29, 44, 46, 51, 52, 53, 72, 77, 78, 108, 111, 113, 114, 108, 132, 140, 212, 218, 221, 262, 263, 264, 266, 286, 289, 291, 330, 338
 activity 72
 and Impaired Glucose and Insulin 111
 calmodulin-requiring 29
 cytochrome 330
 essential metabolic 140
 expression and activity of 44, 46
 fibroblasts release 132
 flavo-heme homodimer 108
 heterotrimeric 212
 inhibiting insulin-degrading 338
 insulin-degrading 12
 reductase 53
 superoxide-producing 52
Enzymes dimethylarginine 70
 dimethylaminohydrolase 70
Epidermal growth factor (EGF) 131, 133
Escherichia coli 90, 93
Estrogen deficiency 162
Euglycemic hyperinsulinemic clamp technique 272
Excitatory synaptic development 240
Exocytosis 11, 12, 215
 insulin granule 12, 215
Expression 44, 45, 46, 49, 50, 51, 69, 72, 97, 109, 135, 147, 163, 169, 198, 285, 309, 313
 accelerating protein 147
 and activity 69, 72, 147, 285
 collagenase 169
 of pro-insulin genes 46

The Role of Nitric Oxide in Type 2 Diabetes 355

 of transcriptional regulators 313
Extracellular signal-regulated protein kinase 243
Extracorporeal shock-wave therapy (ESWT) 148
F
Factors 97, 109, 140, 164, 166, 170, 242, 265, 292
 chemokine stem cell 140
 inflammatory 265, 292
 necrotic 242
 nuclear 109, 166, 170
 osteogenic 164
 signaling-related 97
Fasting 3, 13, 47, 74, 196
 hyperglycemia 13
 insulin 196
 plasma glucose (FPG) 3, 74
 serum concentration 47
Fasting glucose 273, 310, 314
 and insulin 310
Fatty acid oxidation pathway 216
Fatty acyl-CoA synthase 214
Fibrinolysis 214
Fibroblast regeneration 139
Fibroblasts 128, 129, 131, 132, 134, 135, 136, 140, 141, 143, 149
 human diabetic 143
Fibronectin 134, 135
Flux, glycolytic 12
Food 219, 306
 consumption 219
 processing methods 306
Formation 163, 240
 dendritic spine 240
 osteoclast 163
Forsythensis 96
Fractional synthesis rate (FSR) 46, 47, 288
Fracture healing 162, 163, 164, 165, 166, 172
 delayed 165, 166
Fructosamine 272

Function 16, 27, 39, 128, 132, 133, 139, 163, 168, 173, 192, 219, 223, 240, 261, 325
 bone cell 168
 endothelial cell 219
 intestinal metabolic 261
 neuronal 240
 osteoblast 173
 osteoclast 173
Fusobacterium nucleatum 95, 96

G

Gastric 49, 113
 ascorbic acid release 49
 cancer 113
 Gastrin-releasing peptide (GRP) 9
 Gene 107, 108, 147, 248
 polymorphisms 107, 108, 248
 vector technique 147
 Genotype frequency distributions 116
 Glimepiride phosphorylates 216
 Glomerular filtration rate (GFR) 75, 193, 271, 291
 Glucagon secretion 9, 10, 219
 Glucoamylase 221
 Glucokinase 9, 11, 43, 214
 Glucolipotoxicity 19
 Gluconeogenesis 5, 6, 7, 9, 15, 44, 46, 213, 311
 hepatic 6, 7, 44, 46
 reducing cellular 213
 renal 6, 7, 9
 Glucose 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 41, 42, 43, 45, 46, 98, 112, 191, 199, 202, 239, 271, 295, 303, 304, 308, 310, 311, 312, 316, 333, 334, 335, 337, 338, 339
 concentration 3, 4
 fasting blood 5
 homeostasis 1, 2, 3, 5, 7, 8, 9, 46, 98, 271, 295
 insulin homeostasis 338
 intolerance 41, 191
 oxidation 7, 333, 335

phosphorylates 11
 stimulated insulin secretion (GSIS) 10, 12, 42, 43, 45, 46, 199, 202, 308, 310, 311, 312, 337, 339
 tolerance 41, 112, 303, 304, 308, 310, 311, 316, 338
 transporter 9, 43, 46, 202, 334
 utilization 3, 5, 6, 10, 12, 14, 98, 239
 Glucose phosphorylation 4, 11, 12
 venous plasma 4
 Glucose disposal 10, 43, 45, 47, 50, 75, 333, 190, 191
 impaired insulin-mediated 75
 insulin-induced 190, 191
 insulin-mediated 47, 333
 insulin-stimulated 50
 Glucose metabolism 11, 39, 42, 44, 46, 95, 97, 99, 111, 190, 214, 271, 337, 340
 hepatic 44, 46
 impaired 95, 97, 99, 190
 Glucose production 5, 6, 12, 14, 18, 212, 213, 214
 hepatic 5, 18, 212, 214
 reducing hepatic 212, 213
 Glucose transport 11, 12, 332, 335
 insulin-stimulated 335
 Glucose uptake 7, 13, 15, 43, 44, 45, 199, 213, 214, 216, 244, 249, 332, 333, 335, 339
 hepatic 214
 insulin-dependent 216
 insulin-independent 44
 insulin-induced 332, 333, 335
 insulin-sensitive 214
 reducing insulin-stimulated 199
 Glucotoxicity 19
 Glutaminase 286
 Glutamine 268, 287
 supplementation 287
 synthetase 268
 Glyceraldehyde-3-phosphate dehydrogenase 44, 46
 Glycine amidinotransferase 264
 Glycogenesis 10, 44, 46
 Glycogenolysis 5, 6, 9, 44, 46
 glucagon-stimulated 44, 46

Subject Index

hepatic 6
Glycogen 46, 97, 171
 phosphorylase 46
 synthase 46, 97
 synthase kinase 171
Glycogen synthesis 15, 98, 333, 335, 339
 reduced insulin-mediated 335
Glycolysis 7, 216
Glycosaminoglycans 134, 192
Glycosidases 330
Glycosylated hemoglobin 53, 54, 303
Gracilibacteria 88
Griess reaction 142
Growth factor(s) 14, 131, 133, 134, 135, 147,
 168, 169, 170, 242, 307
 epidermal 131
 keratinocyte 133
 platelet-derived 131
 receptor binding protein-2 14
 transforming 131, 147, 169, 170, 242
 vascular endothelial 133, 147
Growth hormone 168
Guanosine triphosphate cyclohydrolase 266
Guanylate cyclase (GC) 31, 163, 325

H

Hair follicles 133
Heart failure 68, 172, 196, 223, 328
 chronic 68
 congestive 196
Hematopoietic osteoclast progenitors 168
Hemodynamic abnormalities 191
Hemostasis 131, 132, 135
Hepatic 13, 46
 arterial circulation 46
 insulin resistance and hepatic glucose 13
Hepatic glucose 5, 6, 13, 18, 212, 213, 214,
 219
 production (HGP) 5, 6, 13, 18, 212, 213,
 214
High 214, 218, 274
 ensity lipoprotein cholesterol 214, 218, 274
 frequency ultrasound technique 218

The Role of Nitric Oxide in Type 2 Diabetes 357

Hip fractures 162, 173
Homeostasis 20, 28, 39, 89, 90, 107, 111, 131,
 198, 239, 263, 272, 275, 325, 331
 cardiometabolic 263
 energy 214
 insulin-glucose 275, 331
 metabolic 20, 90
 oral 89
Hormones, thyroid 168
Human 78, 88, 148, 215, 216, 218, 220, 295
 endothelial cells 78, 216
 oral microbiota database (HOMD) 88
 umbilical vein endothelial cells (HUVECs)
 148, 215, 218, 220, 295
Hypercholesterolemia 68
Hyperglycemia 16, 41, 49, 50, 51, 52, 130,
 131, 172, 173, 211, 212, 218, 219, 270
Hyperglycemic conditions 9, 54
Hyperhomocysteinemia 274
Hyperinsulinemia 19, 41, 42, 44, 46, 52, 111,
 117, 271, 338
 diet-induced 41
Hyperinsulinemic-euglycemic clamp
 technique 315
Hyperlipidemia 130
Hypersecretion 19
Hypertension 68, 108, 112, 119, 191, 210,
 260, 261, 265, 274, 303, 304
 isolated systolic 274
Hyperuricemia, asymptomatic 196
Hyperuricosuria 191, 193
Hypocalcaemia 173
Hypoglycemia 4, 9
Hypothyroidism 306
Hypoxia-inducible factor (HIF) 44, 46, 140

I

Immune system 89
Impaired 1, 2, 3, 195, 244, 272, 294
 brain insulin signaling 244
 fasting glycemia (IFG) 1, 2, 3, 195, 272,
 294
Impaired glucose 1, 2, 3, 111, 195, 272, 273

- and insulin 111
- tolerance (IGT) 1, 2, 3, 195, 272, 273
- Infected wounds 144
- Infection, microbial 130
- Inflammation 39, 44, 89, 95, 96, 97, 98, 129, 131, 132, 135, 139, 142, 165, 167, 195
 - chronic 195
 - gingival 89
 - hyperglycemia-induced 96
 - systemic 97
- Inflammatory response 128, 129, 149, 244
- Infusion 241, 291, 335
 - intraventricular 241
- Inhibited 332
 - adrenaline-stimulated lipolysis 332
 - glucose-induced insulin release 332
 - glucose-induced insulin secretion 332
- Inhibiting arginase 295
- Inhibition, enzymatic 136
- Inhibitors 28, 77, 78, 79, 97, 136, 137, 163, 171, 173, 196, 210, 212, 218, 220, 221, 222, 264, 334
 - allosteric 264
 - cyclooxygenase 28
 - serine protease 97
 - xanthine oxidase 196
- Injury 79, 129, 130, 131, 132, 133, 141, 148, 247
 - inflammatory 247
 - ischemia-reperfusion 79
 - renal 79
 - spinal cord 130
- Insulin 1, 2, 5, 10, 12, 13, 14, 15, 16, 17, 32, 40, 41, 43, 46, 97, 111, 190, 191, 199, 200, 218, 219, 239, 240, 241, 243, 294, 295, 304, 310, 332, 334, 335, 337, 338, 340
 - biosynthesis 46
 - content, pancreatic 310
 - degrading enzyme (IDE) 12, 338
 - effects 17
 - expression 239
 - free fatty acid 295
 - independent pathways 5
 - metabolism 40, 41, 111, 304, 332, 340
 - regulation 295
 - secretion pathway 12
 - sensitive tissues 17, 190, 191, 199
 - signaling pathways 1, 14, 15, 199, 200, 238, 239, 241, 335
 - signal transduction pathway 111
 - stimulated tyrosine 199
 - therapy 2
 - tolerance 310
 - upregulating 218
- Insulin concentration 12, 16, 223, 309, 334
 - arterial plasma 334
- Insulin release 215, 217, 218, 221, 332, 336, 340
 - glucose-dependent 218, 221
 - glucose-induced 336
- Insulin resistance 13, 41, 46, 111, 112, 197, 199, 201, 241, 247
 - endothelial 199, 201
 - hepatic 13, 41, 46, 111, 197
 - hyperuricemia-induced 190, 201
 - hypothalamic 241, 247
 - lipid-induced 112
- Insulin secretion 9, 10, 11, 12, 18, 19, 42, 43, 46, 97, 98, 199, 202, 217, 271, 308, 312, 336, 337, 338, 339, 340
 - glucose-induced 10, 336
 - glucose-stimulated 42, 46, 199, 202, 308, 312
 - inhibited glucose-stimulated 337
 - pancreatic 42
- Insulin sensitivity 16, 41, 44, 45, 46, 111, 112, 212, 214, 271, 272, 273, 309, 310, 311
 - hepatic 46, 272
- Insulin signaling 15, 43, 97, 98, 190, 191, 199, 240, 241, 242, 243, 248, 249, 308, 309
 - neuronal 243
- Intracellular proteins 68, 77, 266
 - methylated 68
- Isoforms 42, 43, 44, 107, 108, 109, 110, 111, 135, 136, 212, 213, 246, 264, 265
 - cytosolic 264
- Isolated systolic hypertension (ISH) 274

K

KATP channel activity 336
 Keratinocyte 133
 growth factor (KGF) 133
 migration 133
 Kidney diseases 68, 195, 211
 diabetic 211
 Kinase 14, 15, 239, 242, 246
 activity, intrinsic tyrosine 14
 cyclin-dependent 246
 intrinsic tyrosine 239
 mitogen-protein 15
 Kyotorphin synthase 263

L

Latanoprostene 30, 32
 Lateral hypothalamus (LH) 8
 Lautropia 95, 96
 Leptotrichia 91, 93, 95, 96
 Lipid synthesis 213, 313
 Lipogenesis 10
 Lipolysis 9, 15, 45
 Lipopolysaccharides 97, 98, 139, 192, 265, 292
 Lipoprotein lipase 169, 170, 214, 314
 Lipoxygenase 31
 Liver 5, 6, 7, 8, 12, 16, 44, 69, 192, 201, 268, 286, 290, 304, 311, 312, 313
 enzymes 312
 gluconeogenesis 7
 steatosis 304
 Low-density lipoprotein cholesterol 274
 LPS-activated macrophages 292
 Lymphocytes 133

M

Macrophage(s) 109, 131, 132, 133, 134, 139, 140, 141, 142, 266, 267, 292, 294, 295
 activated 29, 31, 247, 285, 289, 292
 alveolar 109
 dysfunction 142

Macrovascular complications 75
 Maltase 221, 271
 MAP kinases 199
 MAPK pathway 15
 Mechanisms 10, 48, 49, 51, 53, 54, 97, 131, 132, 133, 191, 194, 197, 201, 212, 217, 221, 238, 249, 326, 339
 antioxidant 194
 of insulin secretion 10
 insulin-independent 339
 linking oral dysbiosis 97
 pathogenic 249
 pathological 54, 238
 Mediated gliclazide's actions 218
 Mediating glucose transport 335
 Mediator, endocrine 197
 Medications 89, 210, 212, 214, 317
 anti-diabetic 317
 anti-osteoporotic 171
 oral antidiabetic 214
 Medicine, traditional Chinese 149
 Melanocytes 136
 Mesenchymal stem cells 169, 170
 Metabolic 12, 15, 41, 42, 42, 47, 52, 88, 95, 107, 108, 198, 239
 actions 15, 239
 amplifying pathway 12
 disorders 32, 41, 42, 47, 52, 88, 89, 90, 95, 107, 108, 191, 196, 198, 199, 244, 246, 273, 303, 304
 dysfunctions 41, 47
 effects 32
 health, systemic 89
 properties 90
 syndrome 32, 47, 95, 191, 196, 199, 244, 246, 273, 303, 304
 Metabolic activities 87, 89, 91
 bacterial 91
 Metabolic pathways 263, 287
 down-stream 263
 Metabolism 2, 17, 39, 40, 41, 48, 49, 68, 69, 70, 93, 107, 108, 190, 191, 192, 197, 211, 215, 261, 289, 294, 296, 327
 amino acid 261

enzymatic 327
 gut-liver 289, 296
 lipid 2, 211, 215
 pro-inflammatory 93
 protein 17
 Metalloproteinases 134, 135
 Metformin therapy 223
 Methicillin-resistant *Staphylococcus aureus*
 (MRSA) 144, 149
 Microalbuminuria 76, 118, 269
 Microbiota 15, 96, 100
 periodontal pathogenic 96
 Microcirculation 45, 131, 308
 redistribution 308
 Migration 132, 218
 neutrophil 132, 218
 neutrophil transendothelial 218
 Mitochondrial 31, 32, 45, 52, 195
 biogenesis 32
 dysfunctions 52, 195
 respiration 31, 32, 45
 Mitogen-activated protein kinase (MAPK) 14,
 15, 197, 200, 218, 242
 Mobilization 140, 222
 intracellular calcium 222
 Modulating glucose 215
 Modulation, genetic 243
 Monocytes 133, 330
 Mononuclear leucocytes 337
 Monophosphate 29
 Monotherapy 212, 214, 217, 219, 221
 Morbidity 19, 75, 224
 cardiovascular 75
 Murine macrophages 292
 Muscles 6, 8, 10, 16, 17, 28, 29, 131, 136,
 211, 213, 214, 216, 221, 333, 334
 arrector pili 136
 vascular smooth 28, 29, 131
 Myocardial infarction 75, 76, 112, 172, 214,
 216, 221
 Myocytes 15, 109, 328
 skeletal 109
 Myofibroblasts 141

N

Necrosis 97, 338
Neisseria 92, 93
flavescens 92
gonorrhoeae 93
mucosa 92
sicca 92
subflava 92
 Neoangiogenesis 149
 Neovascularization 133, 140, 143, 145, 148
 Nephrectomy 262
 Nerve growth factor (NGF) 133
 Nervous system 29
 Neural nitric oxide synthase 27, 39
 Neurodegeneration 242, 247, 248
 Neuroinflammation 241, 248
 chronic 241
 Neuronal plasticity 239
 Neurons 7, 8, 9, 239, 240, 243, 244, 245
 catecholaminergic 8
 glucose-sensing 7, 8
 postsynaptic 240
 temporal cortical 245
 Neuropathology 244
 Neuropathy 3, 128, 130, 330
 autonomic 130
 diabetic 330
 Neuropeptides 3, 9
 Neurotransmission 244
 Neurotransmitter release 244
 Nitrate 223, 309
 nitrite-no pathway 223
 therapy 309
 Nitrate reductase 87, 90
 cytoplasmic assimilatory 90
 membrane-associated cytoplasmic 90
 periplasmic 90
 Nitric oxide 27, 32, 39, 93, 135, 142, 147,
 200, 238, 337
 based treatment of diabetoporosis 170, 171
 deficiency 27, 39
 endothelial 32, 200
 homeostasis 93

Subject Index

metabolites 142, 147
reduced 238
release 337
synthesis 135
Nitric oxide synthase 41, 49, 107, 238, 246,
260, 263, 303
constitutive 41, 49
neuronal 107, 238, 246
Nitrite reductase 87, 90
copper-containing 90
Nitrospirins 327, 329
Nitrogen monoxides 327
Nitroglycerin 31, 163, 171, 172, 327
Nitrosation 247
Non-enzymatic glycation 211
Non-Hodgkin lymphoma 307
Nucleotidase 192
Nutrients 3, 6, 133, 140, 317
digested 6

O

Oral 96, 223, 315
glucose insulin sensitivity, (OGIS) 315
microbiome community 96
microflora 223
Oral microbiota 49, 87, 88, 89, 90, 93, 94, 95,
96, 99
composition 88, 89
Organic nitrates 171, 172, 326, 327, 329
Ornithine 52, 138, 260, 263, 264, 267, 268,
269, 270, 284, 286, 287, 288, 290, 293
aminotransferase 138, 260, 263, 268, 286,
288
carbamoyltransferase 288
decarboxylase 138, 260, 263, 268, 284,
286, 288
transcarbamylase 260, 263, 264, 268, 284,
286
Osteoarthritis 330
Osteoblastogenesis 171
Osteoclastogenesis 168, 171
Osteoclasts 162, 163, 166, 168, 169, 171
inhibiting 171

The Role of Nitric Oxide in Type 2 Diabetes 361

Osteocytes 163, 164, 166, 168, 169
Osteogenesis 163, 169
Osteonecrosis 173
Osteopenia 164
Osteoporosis 161, 162, 164, 167, 171, 172,
173
Osteoporotic fractures 161, 162, 164, 167,
170, 171
Osteoprotegerin 97, 166, 170
Oxidation 194, 213, 216, 313
fatty acid 213, 216, 313
induced 194
Oxidative 10, 213
glucose metabolism 10
phosphorylation pathway 213
Oxidative stress 48, 51, 68, 70, 98, 161, 165,
166, 167, 190, 191, 195, 197, 284, 285,
309
diabetes-induced 309
induction of 191, 195
Oxidoreductases 330
Oxygen metabolites 97
Oxygen pressure 192, 273
transcutaneous 273
Oxyhyponitrate 331

P

Pancreatic cancers 307
Parasympathetic stimulation 9
Paraventricular nucleus 8
Parkinson's disease 113
Pathogenesis 17, 19, 69, 241, 249
Pathological effects of hyperuricemia 194
Pathologies 238, 240, 241, 244, 247
neurodegenerative 244
Pathway 15, 39, 40, 43, 45, 54, 135, 136, 138,
197, 261, 263, 261, 264, 286, 289, 303,
304, 325, 336
biosynthesis 261, 286
catabolic 261, 264
glycolytic 45, 336
inflammatory 197
pro-inflammatory 197

- Pentaerythritol tetranitrate 327
 Peptide 9, 218, 132
 antimicrobial 132
 glucose-dependent insulinotropic 218
 vasoactive intestinal 9
 Periodontitis 90, 95
 Peripheral arterial disease (PAD) 128, 130, 131, 273
 Peripheral vascular resistance 315
 Peroxisome, nuclear transcription factor 214
 Peroxynitrite 52, 140, 194, 214
 production 52
 Phagocytosis 132
 Phenol vitamin 330
 Phenotype 19, 134
 mesenchymal cell 19
 myofibroblast 134
 Phosphatase 51, 240, 242
 protein tyrosine 240, 242
 Phosphodiesterase 29, 31, 33
 cyclic nucleotide 31
 Phosphoenolpyruvate carboxykinase 44, 46, 314
 Phosphorylating 249
 Phosphorylation, tyrosine 110
 Pituitary adenylate-cyclase 9
 activating peptide (PACAP) 9
 Plasma 10, 51, 295
 arginase activity 51, 295
 glucagon 10
 restored 295
 Plasma glucose 3, 99, 269, 304
 postprandial 304
 Polycystic ovary syndrome 15, 195
 Polyphosphatase 242
 Porphyromonas 91, 96
 Porphyromonas gingivalis 90, 95, 96, 99
 Post-prandial hyperglycemia 7
 Post-receptor pathways 16
 Postsynaptic densities 239
 Pressure 30, 32, 129, 130
 intraocular 30, 32
 related trauma 130
 ulcers 129
Prevotella 92, 95, 96
 copri 95
 melaninogenica 92
 nigrescens 96
 salivae 92
 Process 70, 213
 energy-consuming 213
 methylation 70
 Production 40, 50, 52, 67, 73, 77, 78, 89, 131, 136, 139, 143, 199, 198, 220, 240, 242, 265, 266, 267, 274, 285, 288, 291, 292, 294, 295
 bacterial acid 89
 cytokine 139, 294
 free fatty acid 131
 nitric oxide 40, 288
 ornithine-urea 274
 oxidase-dependent 199
 Progressive neurodegenerative disorder 239
 Proinflammatory cytokines 242, 248, 249
 Prostate cancer 172
 Protein 51, 67, 68, 70, 71
 arginine methyltransferases 51, 67, 68, 70, 71
 hydrolysates 71
 Protein kinase 14, 15, 43, 44, 46, 49, 54, 111, 128, 130, 140, 197, 200, 201, 218, 221, 239, 242, 247
 A (PKA) 221
 B (PKB) 14, 15, 43, 46, 49, 111, 140, 200, 239, 247, 334
 C (PKC) 49, 50, 128, 130, 200
 G (PKG) 43, 44, 54
 mitogen-activated 14, 197, 200, 218, 242
 Proteins 40, 43, 45, 68, 69, 70, 71, 72, 89, 111, 114, 139, 141, 142, 214, 249, 262
 dietary 262
 fatty acid-binding 214
 heat shock 249
 metabolize 89
 Proteobacteria 88, 89, 95, 96
 Proteoglycans 134
 Proteolysis 69, 289
 Proteolytic enzymes 132, 141
 zinc-dependent 141
 Pulmonary hypertension 329

Purine nucleoside phosphorylase 192

R

Raf fibrosarcoma 14
Ralstonia pickettii 95
 Rapamycin 46, 239
 Reaction 108, 110, 136, 140, 146, 194, 327, 332, 337
 consecutive monooxygenation 108
 photochemical 136
 trans-nitrosation 337
 Reactive oxygen species (ROS) 41, 128, 131, 197, 199, 200, 202, 218, 238, 242, 245, 249, 309, 314, 331
 Receptor 12, 14
 mediated endocytosis 12
 tyrosine kinase (RTK) 14
 Regulates insulin secretion 46
 Regulation, metabolic 212
 Renal 76, 77, 112, 291, 293, 294
 disease, chronic 77
 function 76, 77, 112, 294
 reabsorption 293
 synthesis 291
 Renal failure 211, 329
 ischemic acute 329
 Respiratory chain, hepatic mitochondrial 212
 Retinopathy 3, 67, 74, 75, 118, 119
 Rheumatoid arthritis 114
 Risk 172, 173, 194, 306, 307
 of cardiovascular diseases 173, 194, 307
 of colorectal cancer 307
 of hip fractures 173
 of prostate cancer 172
 of thyroid cancer 306, 307
 RNA processing 70
 ROS production 51, 132, 199, 242
 diabetes-induced 51
 reducing 242
Rothia 92, 99
 dentocariosa 92, 99
 mucilaginoso 92
 Roussin's red salt (RRS) 328

S

Salivary glands 91, 110
 Schizophrenia 113
 Secretions 9, 214, 218
 epinephrine 9
 Selenomonas 96
 Sensory neuropathy 130
 Sepsis 265, 287
 Sex hormones 168
 Signaling 3, 39, 48, 49, 54, 197, 239, 242, 244, 249
 adiponectin 249
 hormonal 3
 redox-dependent pro-inflammatory 197
 Signaling pathways 307, 325, 339
 canonical insulin 339
 Signal transduction 70, 134
 insulin-mediated 308
 Single nucleotide polymorphisms (SNP) 74, 107, 113, 114, 324, 325, 326, 327, 328, 329, 332, 333, 334, 335, 336
 Sirtuin, protein deacetylase 338
 Skin 7, 110, 133, 135, 136, 137, 144, 173, 330
 eczema 173
 infections, treating 144
 rashes 173
 regeneration 133
 Skin wounds 130, 141, 143, 148
 excisional 141
 Smooth muscle relaxation 29
Staphylococcus sciuri 93
 Stenosis, infantile hypertrophic pyloric 113
 Stomach cramping 274
 Streptozotocin 112, 143, 147, 312, 314
 Stress 15, 112, 213, 243
 metabolic 112, 213, 243
 Stroke 68, 75, 76, 211, 214, 223
 Superoxide dismutase 314
 Supplementation, dietary 147
 Sydnonimines 326, 328
 Synaptic plasticity 240, 243, 249
 Synergistic action 329

Synovial fluid 192
 Synthase 29, 30, 32, 33, 39, 67, 68, 107, 108,
 147, 161, 162, 198, 240, 241, 242
 isoforms 39
 Synthetase 29, 284, 286
 carbamoyl phosphate 284, 286
 Systemic insulin resistance 190, 191, 197,
 199, 238, 244, 248, 308
 Systolic blood pressure (SBP) 272, 273, 274,
 328

T

Tannerella forsythia 95, 96
 Tartrate-resistant acid phosphatase (TRAP)
 12, 165, 166
 Tetracycline antibiotics 136
 Therapeutic 53, 143, 224, 239, 324
 agents 143, 239, 324
 anti-diabetic applications 339
 applications 53, 224
 Thermogenesis 9
 Thyroid cancer 306, 307
 Tissue 97, 131
 acidosis 131
 dysfunction 97
 Transcription factors 109, 169, 200, 202
 adipogenic 169
 osteogenic 169
 Translocation 43, 45, 46, 97, 223, 308, 334
 insulin-independent 44
 Transport 46, 266
 insulin transendothelial 46
 transmembrane 266
 Treatment 30, 295, 327, 330
 of angina 30
 of cardiovascular diseases 327
 of high-glucose-incubated endothelial cells
 295
 of osteoarthritis 330
 Tumor necrosis factor 72, 98, 136, 164, 192,
 200, 213, 265, 273, 292, 330
 alpha 213, 265, 292
 inflammatory marker 273

Tyrosine 43, 44, 45, 46, 54, 240
 nitration 43, 44, 45, 46, 54
 phosphatases 240

U

Ulcers 128, 129, 134, 150
 diabetic 129, 134, 150
 Urea cycle enzymes 286
 Uric acid 192
 metabolism 192
 synthesis 192
 Uricase 192
 Urinary glucose excretion 222
 UV radiation 136, 137

V

Vascular 131, 133, 140, 146, 147, 149, 314
 endothelial growth factor (VEGF) 131,
 133, 140, 146, 147, 149, 314
 oxidative stress 314
 smooth muscle cell migration 131
 Vasculogenesis 133, 140, 143
 and angiogenesis 140, 143
 Vasoactive 9, 131
 intestinal peptide (VIP) 9
 metabolites 131
 Vasodilation 129, 140, 214, 220, 273, 315,
 327, 328
 acetylcholine-induced 315
 endothelium-independent 273
 Vasodilatory effects 28, 32, 214, 219, 340
 insulin's 32
 systemic 340
 vascular endothelial 214
 VEGF expression in keratinocytes 140
 VEGF gene 140
 expression 140
 promoter 140
Veillonella parvula 92, 95, 96
 Voltage-dependent calcium channels (VDCC)
 9, 10, 11, 12

W

- Wavelength, photolysis 332
- Wnt inhibitors 166
- Women 162, 165, 171, 192, 273
 - postmenopausal 162, 165, 171, 192
 - premenopausal 192, 273
- World health organization (WHO) 3, 13, 210, 211, 305
- Wound 129, 132, 138, 139, 140, 142, 143, 144, 146, 149
 - angiogenesis 140, 143
 - antibiotic-resistant bacteria-infected 144
 - healing process 129, 132, 139
 - homogenate 142
 - induction 149
 - infection 144
 - ischemia 140
 - size-reduction 146
- Wound environment 133, 138
 - acidic 133
- Wound fluid 138, 142, 144, 145, 147
 - hydroxyproline 144, 145, 147
- Wound healing 128, 129, 130, 131, 132, 133, 134, 138, 139, 140, 141, 142, 143, 147, 148, 149
 - accelerated 148
 - full-thickness 149
 - impaired 141, 143

X

- Xanthine oxidoreductase 191
- Xenobiotics 192

Z

- Zucker diabetic fatty (ZDF) 215



Asghar Ghasemi

Asghar Ghasemi, Ph.D., is a Research Professor of Medical Physiology at the Shahid Beheshti University of Medical Sciences. Prof. Ghasemi earned his Master's degree of Science in Medical Physiology from Tehran University of Medical Sciences in 2002 and his Ph.D. in Medical Physiology from Baqiyatallah University of Medical Sciences in 2006. He got interested in nitric oxide research while working as an M.Sc. student at Tehran University of Medical Sciences. This interest was further developed at Research Institute for Endocrine Sciences and since he became an independent investigator. He has been working on the role of nitric oxide and particularly nitrate and nitrite, in type 2 diabetes for more than ten years. At present, his research at the Endocrine Physiology Research Center focuses on the potential therapeutic effects of nitrate and nitrite for treating type 2 diabetes. He has more than 75 international publications in the field of nitric oxide.



Khosrow Kashfi

Khosrow Kashfi, Ph.D., is an Associate Medical Professor of Pharmacology at the City University of New York School of Medicine and is a Fellow of the Royal Society of Chemistry and a Fellow of the Royal Society of Biology. Dr. Kashfi is a trained chemist, has a Master's degree in Polymer Physics and Engineering from Cranfield Institute Technology in England, and a PhD in Pharmacology from the University of Tennessee - The Health Science Center. He got interested in cancer prevention whilst working as a postdoctoral fellow at Cornell University Medical College. This interest was further developed at The Rockefeller University and since he became an independent investigator, he has been working on the molecular targets of nonsteroidal anti-inflammatory drugs (NSAIDs) and their various chimeras. His research is currently focused on the molecular targets of nitric oxide and hydrogen sulfide releasing NSAIDs (NOSH-NSAIDs) in cancer. He is the inventor of this class of pharmaceuticals and holds a number of worldwide patents in this general area.



Zahra Bahadoran

Zahra Bahadoran, Ph.D., is Assistant Professor of Nutrition and Health sciences at Nutrition and Endocrine Research Center, Research Institute for Endocrine Sciences. She got her PhD from the Shahid Beheshti University of Medical Sciences where she continued with her postdoctoral training. Her PhD thesis and further training was focused on the potential therapeutic applications of inorganic nitrate and nitrite from dietary sources in management of type 2 diabetes. Her recent publications are focused on the role of nitric oxide in regulation of carbohydrate metabolism.